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Mouse monoclonal antibodies directed against Pichinde virus (PCV) 
were produced to evaluate their application as vehicles for the delivery of 
antiviral drugs or toxins to virus-infected cells. Four monoclonal 
antibodies, PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D3, were of the IgG2a 
subisotype and reacted with acetone-fixed and live PCV-infected Vero-76 
cells. In vivo stained splenic macrophages derived from PCV-infected 
hamsters that had been injected with fluorescein-labeled PC4.9A6 (FITC-
9A6) demonstrated a 400% increase in total fluorescence over similarly 
treated, non-infected cells when analyzed by flow cytometry. This is an 
indication that FITC-9A6 does have some ability to specifically target PCV-
infected cells in vivo. Radioimmunoprecipitation of viral proteins showed 
that all the antibodies precipitated two different PCV proteins, one of 64,000 
daltons and another of 38,000 daltons. These proteins are, respectively, PCV 
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nucleoprotein (NP) and a breakdown product of NP that is present in PCV-
infected cells. 
An immunofluorescent assay (IFA) for PCV was developed. This IFA 
was used for antiviral drug assays against PCV. The assay was performed by 
adding fluorescein-labeled anti-PCV monoclonal antibody to fixed, virus-
infected cells at 24 h after infection and counting the fluorescent cells. The 
50% effective dose (EDso) for ribavirin against PCV using this IFA was 6.0 
IJ.g/ml. The EDso of ribavirin using inhibition of marginal PCV 
cytopathogenic effect after 12 days was 6.0 IJ.g/ml and using plaque reduction 
after 5 days is 2.5 IJ.g/ml, indicating that this IFA was of comparable 
sensitivity. 
An immunotoxin (IT) was produced by the conjugation of gelonin to 
PC4.9A6. This IT was tested in vivo in PCV-infected MHA hamsters. It was 
not active against the disease at the dosage tested and by the intraperitoneal 
(i.p.) treatment route employed in this study. The positive control, rib-
avirin, administered i.p. for 14 days at a dosage of 40 mg/ ml significantly 
increased the number of survivors. Three of 5 IT toxicity control animals 
developed some humoral response that inhibited PC4.9A6 binding to in-
fected cells. They did not show any humoral response to the gelonin moiety 
of the IT. 
(115 pages) 
CHAPTER I 
INTRODUCTION 
The Arenaviridae family contains a group of viruses that have proven 
to be serious human health threats. Some members of this family of 
viruses, Junin, Machupo, and Lassa (the etiological agents of Argentine 
hemorrhagic fever, Bolivian hemorrhagic fever, and Lassa fever , 
respectively), are endemic in some areas of Africa and South America. 
Mortality rates vary from 3 to 30% of infected individuals during outbreaks 
of these viral diseases ( L \. 
Currently available therapies, such as treatment of patients with 
immune plasma from previously infected individuals, have not effectively 
controlled outbreaks of any of the above-mentioned viral diseases. 
Treatment of these diseases with ribavirin, the antiviral drug that is 
currently the most effective drug against Lassa fever, does not ensure 100% 
survival of the infected individuals (2). Also, it is very difficult to ensure an 
adequate supply of im:-_mne plasma in many of the areas where the 
outbreaks may occur because of the remoteness of the locations and 
inadequate public health facilities available. Because these diseases are 
carried by rodents, it is difficult to determine where the next outbreak might 
occur. There are few effective preventative measures to protect against these 
diseases because of continuing difficulties in developing suitable vaccines 
against the hemorrhagic fever viruses. Thus, the arenaviruses do represent 
a severe health threat in countries where these viruses are endemic. 
Pichinde virus (PCV) is an arenavirus from South America that is much 
less pathogenic to humans but still causes a very severe hemorrhagic disease 
in guinea pigs (1) and hamsters (3). Because of the potential for human 
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disease associated with the more virulent arenaviruses, PCV is a good in 
vivo model for the study of the pathogenesis of hemorrhagic diseases as well 
as for the evaluation of the efficacy of novel antiviral therapies to combat the 
illnesses. 
Because of the dependence of viruses on cellular enzymes and ribosomes 
for protein synthesis and replication, it is very difficult to target a therapeutic 
agent to inhibit only virus-specific biochemical events. Compounds that 
interfere directly with the replication of the viral genome or with the 
synthesis of viral proteins will often inhibit similar events in the 
noninfected host cell. Thus, new means of targeting a· •tiv1ral drugs 
specifically to infected host cells have the potential to significantly increase 
the therapeutic index of an antiviral compound. Theoretically, the targeting 
of antiviral agents to infected cells should bring about a significant decrease 
in overall host toxicity and an accompanying increase in the specificity of 
action of the antiviral agent. 
In this research project, the effectiveness of a new means of targeting 
antiviral drugs or toxins using monoclonal antibodies dire :~ed against 
Pichinde virus (PCV) proteins was studied. Monoclonal antibodies produced 
against PCV were characterized as to their isotype and subisotype, reactivity 
with PCV-infected cells in vitro and in vivo, and reactivity with PCV-specific 
proteins. Also, because of the anticipated low yields of immunoconjugate 
production and the insufficient development of PCV cytopathogenic effect 
(CPE) in cell culture, an antiviral assay that used a minimum of compound 
but that still had a readily determined endpoint was developed. A 
promising anti-PCV monoclonal antibody was conjugated with the plant 
toxin gelonin. The resulting immunotoxin was tested in vivo to determine 
its antiviral effectiveness in preventing the development of hemorrhagic 
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disease in MHA hamsters infected with lethal doses of PCV. The humoral 
responses of the hamsters to the monoclonal antibody and the toxin 
components of the immunotoxin were also studied. 
This study provided a basis for the evaluation of the use of 
immunotoxin conjugates for the treatment of arenaviral hemorrhagic 
disease. Insights were gained into the development of more adequate 
screening procedures for the determination of the suitability of individual 
monoclonal antibodies for use as vehicles for the targeted delivery of 
antiviral drugs and toxins. This study provided an opportunity to test the 
predictive nature of the surface binding and viral peptid1· binding 
characteristics of monoclonal antibodies in determining the adequacy of 
screening procedures used to select monoclonal antibodies for use in this 
drug/toxin delivery system. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
PICHINDE VIRUS 
Initial isolation and characterization of Pichinde virus. Pichinde virus 
was first reported as a new member of the Tacaribe group of viruses by 
Trapido and Sanmartin in 1970 (64). It was isolated from a chronically 
infected South American rodent, Oryzomys albigularis, found in the 
Pichinde v Hey of Columbia, hence the name Pichinde virus. Pichinde 
virus was recovered from the brain, heart, lung, liver, spleen, kidney, 
adrenal gland, serum, and urine of naturally infected animals. It was 
included in the Tacaribe group of viruses because of its reactivity in 
complement fixation (CF) tests with Tacaribe-group immune fluids . Its 
distinctiveness was also established on the basis of CF and plaque 
neutralization tests using Pichinde immune ascites fluids, normal serum, 
and homolog: us serum (43). 
In 1971, the lymphocytic choriomeningitis virus (LCM)-like viruses were 
all classified in the group arenaviruses (53). This included the newly 
discovered Pichinde virus (43) . The group was named from the Latin 
arenosus, or sandy, on the basis of the grainy appearance of the interior of 
the virion when viewed by ultra-thin section (45). The graininess is due to 
the incorporation of host cell ribosomes into the arenavirus virion. This is a 
feature that appears to be specific for arenaviruses. The virus group is now 
the family Arenaviridae. 
Mifune et al. (43) characterized the virus as to its size, thermal stability, 
pH stability, density in sucrose, ether lability, and sensitivity to nucleic acid 
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inhibitors such as 5-iodo-2'-deoxyuridine (IdU), 1-~-D-arabinofurano­
sylcytosine (ara-C), actinomycin D, and 6-azauridine. Their results indicated 
that Pichinde virus was indeed similar to LCM in its physical properties, 
demonstrating a size of 50-100 Jlm, relative heat stability, stability over a pH 
range of 6.0 to 9.0, a buoyant density of 1.18 gfcm3, and an ether-soluble lipid 
envelope. Moreover, it was inhibited by actinomycin D and 6-azauridine, 
known RNA polymerase inhibitors, at concentrations that did not affect the 
replication of DNA viruses. It was also resistant to inhibition by known 
DNA antagonists IdU and ara-C. Arenaviruses have also been shown to be 
inhibited by the known antiviral agent ribavirin {:-2). 
Since the primary isolation of Pichinde virus by Trapido and Sanmartin 
(64) and the initial characterization of the virus by Mifune et a!. (43), much 
work has been done in describing both its genetic and antigenic structure. 
Pichinde virus has been shown to contain several species of RNA. The 
Pichinde virion contains large (L) and small (S) segments of RNA that have 
been shown to be the genomic material of the virus (50, 70). The virion also 
contains host cell ribosomal RNAs of 28 S, 18 S, and :-6 S (13). Size estimates 
for the L RNA segment range from 2.63 x 106 to 2.83 x 106 daltons and for the 
S RNA segment from 1.26 x 106 to 1.31 x 106 daltons, as determined by 
Ramsingh et a!. (50). 
Historically, the arenaviruses have been classified as either Old World 
(e.g., LCM and Lassa viruses) or New World (e.g., Pichinde, Machupo, and 
Tacaribe viruses) depending upon where, geographically, the virus isolates 
were obtained. Because LCM has been isolated in both the Old and New 
World, a second classification based on serological reactivity was developed. 
This classification divides the Arenaviridae into two complexes: i) the LCM 
complex containing Ippy, LCM, Lassa, Mabala, and Mopeia viruses and ii) the 
7 
Tacaribe complex containing Amapari, Flexal, Junin, Latino, Machupo, 
Parana, Pichinde, Tacaribe, and Tamiami viruses. The latter classification is 
based on serological cross-reactivity of the members with both polyclonal 
and monoclonal antibody preparations. Cross-reactive epitopes within each 
complex and also between the two complexes have been demonstrated (71). 
Direct analysis of sequence data from the genomic regions that code for the 
nucleoprotein (NP) and the glycoprotein precursor protein (GPC) confirm 
that Pichinde, Lassa, and LCM are indeed all closely related (7, 58, 68). 
Synthesis of both the NP (molecular mass [m.m.] = 64,000-66,000 daltons) 
and GPC (m.m. = -80,000 daltons) has been mapped to the S segment of the 
Pichinde virus genome (4, 26) . Sequence analysis, combined with 
appropriate S RNA segment DNA probes, has shown that Pichinde-virus-
infected cells contain full length viral and viral-complementary S RNAs. 
Two distinct subgenomic S RNAs were also detected in infected cells. The 
subgenomic viral-complementary mRNA coded for NP and the subgenomic 
virus-sense mRNA codes for the GPC. These observations have resulted in 
the proposal of an ambisense coding strategy to explain how these proteins 
are synthesized from the same viral RNA (4, 7). This ambisense strategy 
denotes only that both the viral-sense and the viral-complementary mRNA 
transcripts can be used to synthesize viral gene products from the viral 
genomic S RNA. 
Pichinde virus has been shown to code for three major proteins. The NP 
makes up an estimated 70% of the entire protein mass of the virus. The 
cleavage products of GPC, GP1, and GP2 make up a total of about 25 % of the 
viral protein mass . There are approximately 400 molecules of each 
glycoprotein on the surface of the virion and approximately 1500 molecules 
of NP on the inside of the virion (9, 69). 
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The m.m.s of the different viral glycoprotein species are disputed in the 
literature (6, 9, 27, 69). Vezza et a!. (69) reported the m.m. for NP to be 66,000 
daltons and the m.m: for GP1 and GP2 to be 64,000 and 38,000 daltons, 
respectively. Harnish et a!. (27) reported the m.m. for NP to be 64,000 daltons 
and the m .m. for GP1 and GP2 to be 52,000 daltons and 36,000 daltons, 
respectively. The difference in the m.m. of GP1 between the two groups is 
difficult to explain. Both experiments were done in a baby hamster kidney 
cell line (BHK-21), suggesting that simple differences in the availability of 
cellular glycosylases will not suffice as the explanation for the observed 
difference. 
Other minor proteins have been reported for Pichinde virus. This 
includes a protein, coded on the L segment of the genome, that is thought to 
be the viral RNA polymerase. It has a m.m. of 200,000 daltons. There are 
also several other minor proteins, ranging from 12,000 to 77,000 daltons, 
whose functions have not yet been identified (9). 
Animal models of Pichinde virus-mediated hemorrhagic disease. Since 
the initial isolation of Pichinde virus in 1971, it has become the prototype 
virus for studying the in vivo pathogenesis of arenaviral hemorrhagic 
disease in small animals such as the Syrian hamster strain MHA (21, 44) and 
the guinea pig strain 13 (32). Pichinde virus is preferred because of its 
extremely low potential for infectivity and disease in humans and also 
because of the reproducibility of the viral infection in these small animals. 
In addition, because it has been adapted to cause a lethal disease in guinea 
pigs, it is considered to be an alternative model to Lassa fever in these 
animals. Lassa fever virus does not produce clinical disease in MHA 
hamsters (32). 
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Pathogenesis of viral hemorrhagic fevers. The comparative study of the 
pathogenesis of Pichinde virus in two different hamster strains reported by 
Murphy et a!. (44) showed that only the MHA strain of adult hamsters was 
susceptible to lethal infection. The L VG strain of Syrian hamsters, though 
showing some signs of disease early in the infection, was able to clear the 
virus completely from its system by day 10 post-infection. 
Infection of MHA hamsters with Pichinde virus resulted in a severe 
hemorrhagic disease in the animals, grossly characterized by edema around 
the eyes, bleeding from the eyes and nose, and diarrhea, as well as a lethargy 
as the disease progressed. Intern >lly, infection of the macrophages in the 
spleen resulted in the depopulation of the organ with destruction of both the 
red pulp and the white pulp regions. In moribund animals, antigenic and 
necrotic tissue was observed to be held in place by only an intact splenic 
capsule. 
In the liver, the Kuppfer cells and hepatocytes were the targets of viral 
infection. Necrotic Kuppfer cells and hepatocytes were present as foci in 
infected livers by day 10. A large am: :mt of cellular debris was present in the 
sinusoids of the organ. The lesions observed in the infected livers have been 
reported to be very similar to the lesions caused by Lassa fever virus in 
humans (44, 72). 
An observation of interest regarding the natural resistance of the LVG 
hamsters to Pichinde virus infection is that this resistance can be abrogated 
by immunosuppression with cyclohexamide. Also, immunosuppression of 
the MHA hamsters with cyclohexamide did not prevent lethal infection 
with the virus. Kenyan et a!. (35) reported that immunosuppression of 
guinea pigs that were later infected with virulent Junin virus resulted in no 
apparent effect on the development of the disease in these animals. They 
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also demonstrated that immunosuppressed animals infected with an atten-
uated strain of Junin developed fatal Argentine hemorrhagic fever, whereas 
the immunocompetent, infected animals did not. Immunosuppression 
prevented the development of antibody-dependent virus-specific cytotoxic 
spleen cell activity. Also, no harmful effects induced by the immune 
response were observed in any of the infected, immunocompetent animals. 
This evidence suggests that, unlike the immune complex-mediated disease 
observed in LCM-infected animals (10), there is a direct role for the 
arenaviruses of the Tacaribe complex and Lassa fever virus in the 
pathogenesis of the hemorrhagic fevers (44). 
The specific mechanisms of viral pathogenesis due to arenaviral 
infection have been difficult to elucidate. Liu (40) has described the effect of 
PCV on the hearts of infected guinea pigs. The beating hearts, observed in 
situ on days 11 to 19 post-infection, showed three types of cardiac 
abnormalities: i) engorgement of the superior and inferior vena cavae with 
an accompanying dilation of the right side of the heart, ii) sluggish cardiac 
contractions and diminished heart rate, and iii) a systolic bulge at th :. apex of 
the right ventricle. Cardiac and other tissues sampled immediately after the 
death of the animals did not manifest any obvious histopathological lesions. 
Jahrling et a!. (32) have previously reported that no virus was recovered 
from the hearts of infected guinea pigs. Thus, there appears to be no direct 
histopathological evidence for an involvement of Pichinde virus in causing 
cardiac dysfunction. 
An earlier study by Liu et a!. does shed some light on how Pichinde 
virus infection may be indirectly involved in producing the observed cardiac 
dysfunction (41). Infection of guinea pigs with Pichinde virus caused an 
increase in the serum levels of the leukotriene L TD4. Leukotrienes are 
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eicosanoids and are related to the prostaglandins. They are synthesized from 
arachidonic acid and have been shown to act as vasoconstrictors and to also 
increase vascular permeability. The leukotrienes LTC4 and LTD4 are 
thought to be the most important components of Slow Releasing Substance 
of Anaphylaxis (SRS-A), which causes smooth muscle contraction often seen 
in allergic asthma. Treatment of infected animals with the LTD4 antagonist 
FPL-55712 led to an increase in mean survival time and food intake as well 
as a decrease in weight loss. Treatment did not mitigate a persistent fever in 
the guinea pigs . These studies propose that infection with Pichinde virus 
induced the overproduction of these leukotrienes and, indirectly, that these 
biochemical "lesions" disturbed the chemical homeostasis of the heart 
muscle, eventually leading to the death of the animal. 
MONOCLONAL ANTIBODIES 
Monoclonal antibody technology. With the introduction of monoclonal 
antibody technology by Kohler and Milstein in 1975 (37), the scientific 
research community was provided a very powerful tool for probing, 
potentially, the molecular secrets of any immunogen. This technology has 
proven itself far superior over conventional polyvalent sera in that: i) 
antibody of a single specificity can be obtained; ii) hybridomas secrete an 
almost unlimited amount of the desired antibody; iii) impure or partially 
purified antigen can be used to produce monospecific antibody; iv) many 
different specificities can be isolated from a single mouse; v) specific B cells 
are enriched during hybridization; vi) low-producing B cells, when fused to 
myeloma cells, become much higher producers; vii) the hybridoma can be 
genetically manipulated to produce non-naturally occurring antibody; and 
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viii) the technique of fusing immortalized cells to normal cells will bestow 
the immortalized phenotype to a variety of cells such as T cell clones (3, 36). 
In 1975, Kohler and Milstein (37) published a paper in which they 
described a technique for fusing antibody-producing B cells with 
immortalized myeloma cells. This technique created a hybridoma that was 
immortalized and that retained the antibody-secreting phenotype of the B 
cell fusion partner. It was quickly recognized that this approach to producing 
antibody of a single, defined specificity would revolutionize nearly all fields 
in biology, biochemistry, and molecular biology. The advent of monoclonal 
ar :ibody technology has not only led to great strides in researching antigen-
antibody interactions, but it has had tremendous impact on such diverse 
fields as the diagnosis and treatment of disease (5, 51); purification of 
proteins and other biomolecules; the development of new, safer vaccines (1, 
34, 60); and the development of customized enzymes (48, 62, 63). This 
technology has also revolutionized the field of immunology, allowing the 
elucidation of the biosynthesis of immunoglobulins, immunoglobulin class 
swiL~ing, and the characterization of many of the subgroups of the T cell 
family of immune cells. These subsets of T cells have now been shown to 
have specific, critical roles in the development of both humoral and cellular 
immunity. 
The production of monoclonal antibodies is accomplished as described 
below. Spleen cells are taken from a donor that has been previously 
immunized with the antigen of interest. These cells are teased from the 
splenic capsule and collected. Myeloma cells that are deficient in 
hypoxanthine or adenosine phosphoribosyl transferase (HPRT or APRT) are 
then mixed with the immune spleen cells, and the cells are then fused 
together via an agent such as polyethylene glycol. The fused cells are then 
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gently suspended in growth media and plated out. The plates are then fed 
with media containing hypoxanthine or adenosine, aminopterin, and 
thymidine. This is done in order to select only cells that have been fused 
together successfully. The selection is based upon the deficiencies in the 
purine nucleotide salvage pathways of the myeloma cells and the inhibition 
of de novo purine nucleotide biosynthesis by aminopterin. Only 
hybridomas that contain a functional salvage pathway, HPRT- or APRT-
containing cells, are capable of growing in the selection media. Theoretically, 
only the hybridomas that meet these requirements can grow, because of the 
presence of the salvage pathway enzym cs HPRT and APRT from the 
immune B cell fusion partner. Unfused B cells and myelomas die after a few 
days of exposure to the selection media (22). 
There are problems associated with the production of monoclonal 
antibodies. Because hybridomas contain 2-10 times the normal complement 
of genetic material, they often throw out the extra chromosomal baggage. 
This can result in a change in the phenotype of the cell. Occasionally, the 
antibody secretory genes are deleted from a.n unstable hybridoma and 
monoclonal antibody production is lost . Other times, the salvage pathway 
genes are lost and the hybridoma dies. Hybridomas that survive selection 
and that are positive antibody producers are cloned by limiting dilution to 
isolate clones derived from individual hybridomas and retested for antibody 
production. It is not unusual for a hybridoma to be recloned and rescreened 
three or four times prior to using it for producing large quantities of 
antibody. 
Therapeutic conjugates employing monoclonal antibodies for directed 
drug or toxin delivery. The concept of using antibodies for the delivery of 
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drugs to infected or malignant tissues can be traced back to Paul Ehrlich who 
postulated the "magic bullet" idea during the late nineteenth century (30) . 
With the advent of monoclonal antibody technology in 1975 (37), it became 
possible to develop antibodies that react specifically with tumor-associated 
antigens. Monoclonal antibodies were made against a variety of different 
tumor cell antigens and were then used experimentally as therapeutic agents 
with the hope of exploiting the exquisite specificity of these molecules in 
destroying malignant tissues (28). It soon became evident that, even though 
monoclonal antibodies were directed against tumor-specific antigens, they 
were much better suited for use as diagnostic reagents, rather than ~s 
therapeutic agents for the treatment of cancer. 
As clinicians were seeking to develop monoclonal antibodies for use as 
therapeutic agents, they were also developing new chemotherapeutic agents 
to specifically inhibit and kill cancer cells. These agents were designed to 
inhibit specific biochemical reactions, such as the methylation of DNA by 
dihydrofolate reductase, that occur at much higher than normal levels in 
rapidly replicating tumor cells. Many of the newly developec 
chemotherapeutic agents were promising against tumor cells in vitro, but 
later proved to be too toxic when tested in vivo. Host toxicity is still the 
single most significant problem associated with cancer chemotherapeutic 
agents. 
As these events took place, other scientists were purifying and 
characterizing potent toxins derived from both bacteria and plants. The 
earliest plant toxins to be purified and characterized were ricin and abrin. 
These were isolated from Ricinus communis (Castor bean) and Abrus 
precatorius (Jequirity bean), respectively (24, 19). At the end of the 
nineteenth century, Paul Ehrlich was able to demonstrate the separate 
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immunological identities of these two toxins by demonstrating that mice 
immunized with either toxin were not protected against lethal challenge 
with the other (19). Several other plant and bacterial toxins, such as gelonin 
(59), pokeweed antiviral protein, modeccin, diphtheria toxin, and 
Pseudomonas exotoxin A ·(14), have since been isolated and characterized for 
use in the construction of therapeutic immunoconjugates for use in cancer 
and antiviral immunotoxin therapy (2, 8). 
Plant and bacterial toxins are composed of either a single A chain protein 
monomer or a heterodimer composed of an A and a B chain. The A chain of 
a heterodimeric toxin contains the catalytic (toxin) domain, whereas the B 
chain usually contains a lectin or lectin-like molecule that mediates binding 
of the entire toxin molecule to sugar residues expressed on the surface of 
cells. The B chain domain also may be important in the translocation of the 
toxin across the cell membrane (2). 
The catalytic domains of A chains of either the monomeric or 
heterodimeric toxins require entry into the intact cell before toxic effects are 
observed. Once inside the cell, the toxins exert their effects on the eukaryotic 
28 S ribosomal RNA. Endo et a!. (16) have demonstrated that ricin, abrin, 
ricin A chain, and modeccin inactivate the 28 S ribosomal subunit by 
modifying both or either the guanosine4323 or adenosine4324 nucleoside 
residues. This effectively shuts down the protein synthesis machinery of the 
cell, resulting in cell death. 
Because of the dissatisfying results obtained in using monoclonal 
antibodies as therapeutic agents for cancer, oncologists soon realized that 
what monoclonal antibodies lacked was the "punch" associated with the 
often too-toxic chemotherapeutic agents (24) . They theorized that by 
combining the specificity of monoclonal antibodies with the potency of 
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chemotherapeutic agents or the newly discovered toxins, the "magic bullets" 
originally put forth by Ehrlich, could finally be produced. Thus, the 
components necessary for the production of the immunoconjugates were in 
place, and the synthesis and evaluation of these agents could begin (38). 
Chemotherapeutic agents, such as methotrexate (15, 20, 33, 46, 55), 
daunomycin, (31, 47, 66), daunorubicin (65, 67), and adriamycin 
(doxorubicin), (56) were covalently attached to monoclonal antibodies 
directed against various tumor antigens. Work was undertaken comparing 
the biodistribution of two distinct chemotherapeutic agents, methotrexate 
and daunom _-cin, that were conjugated separately to a monoclonal antibody 
that reacts specifically with the osteosarcoma 791T. These experiments 
demonstrated that the conjugates were stable over the course of the three-
day experiment. They also demonstrated a 100-fold increase in tumor levels 
of the drugs in the conjugated treated animals over those seen in animals 
treated with free drug. Further, an unrelated monoclonal antibody against 
colon carcinoma HCT8 was conjugated with daunomycin and did not show 
any targeting ~fficacy in the osteosarcoma system (47) . Controls in which 
methotrexate was conjugated to normal mouse IgG did not target the 
chemotherapeutic agent to the tumor xenograft (46). 
Monoclonal antibody-toxin conjugates have been used in attempts to 
inhibit tumor growth in vitro and in vivo. A variety of monoclonal 
antibodies directed against a wide range of mouse and human tumor 
antigens have been conjugated with ricin A chain (25, 49, 52, 57), diphtheria 
toxin (11), gelonin (39, 54, 57), saporin (61), Pseudomonas exotoxin A (17), 
and pokeweed antiviral protein (39, 49). Immunotoxins such as these exert 
their effect on cells by binding to the antigen of interest, moving over the 
surface of the cell until it is over a clatherin-coated pit, being endocytosed 
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into an endosome, and eventually forming a lysosome and releasing the 
toxin from the antibody inside of the cell (12). These immunotoxins have 
for the most part been evaluated in vivo only against human tumor 
transplants in mice or in mouse tumor models. Results from these tests 
have yielded results from no increase in mean survival time to 100% 
protection from tumor development (18, 23). 
Recently, one of the most promising immunotoxins, T101-ricin A chain 
T101-RTA, composed of a monoclonal antibody directed against human COS 
antigen conjugated with ricin A chain, underwent phase I trials in humans. 
The study showed that the immunotoxin was reaching and binding to the 
cells of interest, but that there was no sustained benefit in any of the patients 
(n=4) tested. This was demonstrated to be due to the natural resistance of the 
patients' leukemic cells that were refractile to in vitro treatment with T101-
RTA at levels >2000 ng/ml (29). 
A similar approach to the development of a possible AIDS treatment, 
using a portion of Pseudomonas exotoxin A hybridized to recombinant 
human CD4, was shown to selectively kill HIV ::afected cells in vitro (14) . 
This report reinforces the concept that the immunotoxins can be used for the 
treatment of viral disease. Though this study was done in vitro, it is still 
significant in that it demonstrates that targeted delivery of toxin molecules 
to virally infected cells can take place and achieve the desired results. 
The potential for using both drug-monoclonal-antibody and toxin-
monoclonal-antibody conjugates for the treatment of cancer and viral 
disease is exciting and full of possibilities. Essentially no work has been done 
in the field of treatment of viral diseases with immunoconjugates. 
Researchers have only now begun to investigate the possible application of 
this approach to the treatment of viral disease, particulary with respect to the 
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AIDS epidemic. The gains that are currently being made in this field are 
small but significant and are seminal in providing the groundwork for new 
therapies for the treatment of viral, neoplastic, and genetic diseases. 
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CHAPTER ill 
A NEWLY DEVELOPED IMMUNOFLUORESCENT ASSAY 
FOR DETERMINING THE PICHINDE VIRUS-
INHIBITORY EFFECTS OF SELECTED 
NUCLEOSIDE ANALOGUES 
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An immunofluorescent assay (IFA) for Pichinde virus (PCV), a member 
of the family Arenaviridae, was developed for antiviral drug assays against 
the virus. The assay was performed by adding fluorescein-labeled anti-PCV 
monoclonal antibody to virus-infected cells at 24 h after the ini•:al infection 
and counting the infected cells with an epifluorescence microscope. The 50% 
effective dose (EDso) for a series of nucleoside analogues tested against PCV 
using this IFA was: 2-p-D-ribofuranosylselenazole-4-carboxamide 
(selenazofurin), <1.0~g/ ml; 1-p-D-ribofuranosyl-1,2,4-triazole-3-carboxamide 
(ribavirin), 6.0 ~g/ml; ammonium 1-13-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide-5'-phosphate hydra te (ribavirin-5'-monophosphate), 15.8 
~g/ ml; ammonium 1-13-D-ribofuranosyl-1 ,2,4-triazole-3-carboxamide-5'-
hemisuccinate (ribavirin-5'-hemisuccinate), 14.7 ~g/ml; ammonium 1-13-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide-5'-(2,3-dimethyi)hemisuccinate 
[ribavirin-5'-(2,3-dimethyi)hemisuccinate], 213.5 ~g/ml; 4-hydroxy-1-13-D-
ribofuranosyl-2-pyridone (3-deazauridine), 5.2 ~g/ml; and (5)-9-(2,3-
dihydroxypropyl)adenine, ([5]-DHPA), 471.0 ~g/ml. In comparison, the EDso 
of ribavirin using inhibition of marginal PCV-induced cytopathogenic effect 
after 12 days was 6.0 ~g/ml and using plaque reduction after 5 days was 2.5 
~g/ml, indicating that this IFA was of comparable sensitivity to these other 
tests . 
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The Arenaviridae family contains a group of viruses that have proven 
to be serious human pathogens, with clinical signs of disease presenting as 
hemorrhagic fevers. Some members of this family of viruses, Junin, 
Machupo, and Lassa (the etiological agents of Argentine hemorrhagic fever, 
Bolivian hemorrhagic fever, and Lassa fever, respectively), are endemic in 
some of areas of Africa and South America. Pichinde virus (PCV) is an 
arenavirus from South America that is much less pathogenic to humans but 
causes a very severe hemorrhagic disease in guinea pigs (8) and hamsters 
(12). Ribavirin has previously been shown to have in vitro and in vivo 
antiviral activity against several of the arenaviruses (11, 16). 
There has been an interest in developing a simple arenavirus antiviral 
assay. Standard antiviral assays that depend upon plaque reduction (PR) or 
inhibition of viral cytopathogenic effect (CPE) are not suitable for working 
with PCV because this virus does not cause consistently quantifiable CPE 
(13). This report describes an immunofluorescence assay for use in 
evaluating potential antiviral compounds against PCV. The assay is based 
on enumeration of virus infected cells utilizing fluorescein-labeled anti-PCV 
monoclonal antibody 24 h after exposure of cells to the virus. Utilization of 
this assay as an antiviral test appears reproducible and provides the means to 
rapidly screen many compounds while reducing both the sample size and 
assay time. 
L 
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MATERIALS AND METHODS 
Cells. The African green monkey kidney cells, Vero-76 cells, used in this 
study were obtained from the American Type Culture Collection (Rockville, 
MD) . Cells were passaged in minimum essential medium (MEM, GIBCO, 
Grand Island, NY) supplemented with 9% fetal bovine serum (FBS, HyClone 
Labs, Logan, UT) and 50 Jlg gentamicin/mi. For antiviral assays, cells were 
seeded at 4 x 104 cells/well in 96-well polystyrene cell culture plates (Corning, 
Corning, NY) and incubated at 37°C in humidified 5% C02 in air. The plates 
were used 20-24 h after seeding. 
Virus. PCV strain An 4763 was provided by Dr. Joseph D. Gangemi, 
University of South Carolina School of Medicine, Columbia, SC. Virus 
stocks were prepared in Vero cells from twice plaque-purified PCV. The 
virus was grown at 37°C and was harvested 2-3 days post-virus exposure, 
aliquoted into ampules, and stored at -90°C until used. The virus stock used 
in these experiments had a titer of 4 x 105 plaque-forming units (pfu)/ml. 
The virus was also grown in the following cell lines: KB, human oral 
epidermoid carcinoma, HeLa markers, ATCC CCL 17; BHK, BHK-21, kidney 
cells derived from one-day-old Syrian hamsters, ATCC CCL 10; MDBK, 
Madin-Darby bovine kidney cells, ATCC CCL 22; L, L929 cells, in growth 
medium containing 10% fetal bovine serum rather than 10% horse serum; 
L929, NCTC clone 929, mouse connective tissue cell line grown in media 
supplemented with 10% horse serum, ATCC CCL 1; Vero, Vero-76, African 
green monkey kidney, ATCC CRL 1587; MOCK, Madin-Darby canine kidney 
cells, ATCC CCL 34; MRC-5, fetal male human lung diploid cells, ATCC CCL 
171; WI-38, fetal female human lung diploid cells, ATCC CCL 75; LLC-
MK2D, rhesus monkey kidney, ATCC 7.1; HaK, adult Syrian hamster kidney 
29 
cells, ATCC CCL 15; MA-104, embryonic African green monkey kidney cells, 
passage 52 from Dr. Mary Estes, Baylor University, Houston, TX. This was 
done in an attempt to find a cell line in which PCV would produce 
consistently quantifiable CPE. 
Antiviral compounds. Ribavirin (1-~-D-ribofuranosyl-1,2,4-triazole-3-
carboxarnide) and 3-deazauridine (4-hydroxy-1-~-D-ribofuranosyl-2-pyridone) 
were provided by ICN Pharmaceuticals (Costa Mesa, CA). Selenazofurin (2-~­
D-ribofuranosylselenazole-4-carboxarnide) was provided by Dr. P. D. Cook, 
Warner Lambert/Parke Davis, Inc. (Ann Arbor, MI) . Ribavirin-5'-
rnonophospha te (ammon; urn 1-~-D-ribofuranosy 1-1 ,2,4-triazole-3-carboxarn-
ide-5 '-phosphate monohydrate), ribavirin-5'-hernisuccinate (ammonium 1-
~-D-ribofuranosy 1-1,2,4-triazole-3-car boxarnide-5'-hernisuccinate), and rib-
a virin-5'-(2,3-dirneth yl)hernisuccina te (ammonium 1-~-D-ri bofuranosyl-
1,2,4-triazole-3-carboxarnide-5'-[2,3-dirnethyl]hernisuccinate) were synthe-
sized in one of our laboratories (M.D.). The (5)-DHPA [(S)-9-(2,3-dihydrox-
ypropyl)adenine] was provided by Dr. Erik De Clercq, Rega Institute for 
Medical Research, Leuven, Belgium. All compounds were stored in sealed 
vials at room temperature in the presence of dessicant. For antiviral testing, 
the compounds were solubilized in MEM and then stored at 4°C until used. 
Monoclonal antibodies. The hybridorna cell lines PC4.9A6 and PC4.9D3 
were derived through the polyethylene-mediated fusion of FOX-NY 
myeloma cells with the splenocytes from RBF/Dn mice. The spleen donor 
mice had been hyperirnmunized with homogenized brain tissue in Freund's 
adjuvant (Sigma, St. Louis, MO) from suckling RBF/Dn mice that had been 
infected intracranially with PCV. The adenosine phosphoribosyltransferase 
procedure as described by Taggart and Sarnloff (17) was used to select for 
hybridorna cell lines. The PC4.9A6 and PC4.9D3 hybridorna cell lines 
30 
secreted anti-PCV monoclonal antibodies of the IgG2a subisotype. The two 
monoclonal antibodies bind different epitopes of a PCV protein on PCV-
infected cells. The hybridoma lines had been subcloned twice and the cells 
were in the exponential growth phase when injected into recipient (BALB/c 
x RBF/Dn) Ft mice that had been primed by intraperitoneal injection with 
1:0 ml of 2,6,10,14-tetramethylpentadecane (pristane). The resulting ascites 
fluids contained anti-PCV monoclonal antibodies at concentrations ranging 
from 5-15 mg/ml. 
Preparation of fluorescein-labeled monoclonal antibodies. 
Immunoglobulins, predominantly monoclonal ant :bodies, were isolated 
from ascites fluids by precipitation with ammonium sulphate and further 
purified by affinity chromatography on protein A using the Bio-Rad Affi-Gel 
Protein A MAPS II Kit (BIO-RAD Laboratories, Richmond, CA) . 
Immunoglobulin samples were dialyzed against 0.1 M Na2HP04, pH 9.0. 
Following dialysis, precipitates were removed by centrifugation for 15 min at 
550 x g . Sufficient fluorescein isothiocyanate (FITC, Isomer 1 from Sigma 
Chemical Co., St. Louis, MO) was added to result in a ; rotein to FITC wt:wt 
ratio of 50:1 in the conjugation reaction mixture. The FITC was added as a 
solution containing 1.0 mg/ml of FITC dissolved in 0.2 M Na2HP04, pH 9.0; 
this FITC solution was prepared just before addition to the immunoglobulin. 
The conjugation of fluorescein to protein was then accomplished by bringing 
the pH of the immunoglobulin-FITC mixture to 9.5 by dropwise addition of 
0.2 M Na3P04 and allowing the reaction to proceed at 25°C for 2.5 h. The 
conjugation conditions were selected to yield a fluorescein to protein ratio in 
the final conjugate of approximately 10 fluorescein molecules per molecule 
of immunoglobulin (4). The unconjugated FITC was removed by dialysis 
against Dulbecco's phosphate-buffered saline: 0.5 mM MgC12, 2.7 mM KCl, 1.5 
~ 
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mM KH2P04 , 8 mM Na2HP04 and 140 mM NaCI, pH 7.2 (PBS), containing 
0.1% sodium azide. The fluorescein-labeled monoclonal antibody 
preparations were then further purified by gel exclusion chromatography on 
Sephadex G-75 (Pharmacia Fine Chemicals, Piscataway, NJ). The resulting 
fluorescein labeled monoclonal antibody preparations were titered in a direct 
immunofluorescent cell assay using PCV-infected Vero cells. There was 
only the slightest nonspecific staining at dilutions of 1:100 or greater, while 
the specific staining was very clear and intense out to dilutions of at least 
1:1,600. 
Immunofluorescence assay for PCV-infected ~ells. The IFA for PCV-
infected cells used a cocktail of fluorescein-conjugated murine monoclonal 
antibodies towards PCV designated PC4.9A6 and PC4.9D3. These were diluted 
to approximately 0.01 to 0.03 mg protein/ml and then combined in equal 
volumes in PBS prior to use. Unused antibody was kept frozen at -20°C until 
thawed immediately prior to use. At 20-24 h postinfection (p.i.), the medium 
was removed from the wells of the 96-well plates and the cells were allowed 
to dry thoroughly at room temperature. If the cell she_ts were not allowed to 
dry thoroughly prior to adding the 80% acetone fixative, many of the cells 
would detach from the well during the fixation and staining procedures. 
The cells were then fixed in 80% acetone by adding cold distilled water (50 
Jll/well) followed by immediate addition of cold (-15°C) acetone (200 
J.!l/well) to the water in each well. If the acetone and water were mixed prior 
to addition to the wells, or if the acetone was added first, the plastic was 
etched, thus spoiling the specimens for microscopic examination. The 
fixation was allowed to proceed for 5 minutes and then the fixative was 
poured from the plate and the cell sheets were allowed to dry thoroughly. 
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Cells were either immunostained immediately after drying or stored at 
-l5°C. 
Fluorescein-labeled monoclonal antibody towards Pichinde virus was 
used at a dilution of 1:500 to provide intense specific staining with only 
minimal nonspecific background. For immunostaining, 50 111 of the 
fluorescein labeled antibody was added to each well and immunostaining 
was allowed to proceed at 37°C for 1-2 h before the immunostain was poured 
from the plate. The plate was inverted on absorbent paper and allowed to 
drain, a drop of mounting medium (5) was added, and immunostained cells 
were viewed through the bottom of the plate using a 16X objective and lOY 
eyepieces on a Zeiss epifluorescence microscope. The number of fluorescent 
cells in one strip across the center of each well was counted and the total 
fluorescent cells per well determined as described by Barnett et a!. (2) and Tu 
eta!. (18). The multiplication factor calculated for the one strip counts in this 
study was 6.36. 
Immunofluorescence antiviral assay (IFA) and toxicity evaluation. 
Growth medium was aspirated from confluent monolayers of Vero cells 
growing in 96-well culture plates and 100 111 of PCV diluted in MEM with 2% 
FBS was added to the appropriate wells. The virus inoculum was such that 
there were approximately 10 fluorescing cells per microscope field in virus 
control wells, the multiplicity of infection (MOl, the ratio of infectious virus 
to cells) was approximately 0.002. The virus was allowed to adsorb for 30 
minutes at room temperature after which time 100 111 of test compound 
diluted in MEM was added without removing the virus inoculum. Seven 
concentrations of test compound were used: 1000, 320, 100, 32, 10, 3.2 and 1 
1-!g/ml. The plates were then sealed with plastic wrap (Saran Wrap™, Dow 
Chemical Corp.) and incubated for 20-24 h at 37°C. The cells were fixed and 
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immunostained to detect PCV-infected cells as described above. The number 
of fluorescing cells in treated wells was determined and compared to the 
number of fluorescing cells in wells without drug. Each assay included 
toxicity controls as well as virus and normal cell controls similar to a virus 
reduction assay described previously (15). Three virus-containing wells were 
used for each dose, with one additional well being used for toxicity controls 
(cells + sterile virus diluent + drug). Six wells on each plate were used for 
normal cell controls (cells + sterile virus diluent + drug diluent). Six wells 
on each plate were used for virus controls (cells +virus + drug diluent) . The 
antiviral activity was expressed as the 50% effective dose (EDso), which was 
the concentration of drug required to reduce the number of fluorescing 
infected cells by 50%. The EDso was determined by plotting the percent 
inhibition versus compound concentration on a semilogarithmic chart. 
Drug toxicity was evaluated by examining the toxicity control cells 
microscopically for morphological changes, when compared with normal 
cell controls. The 50% cytotoxic dose (CD50) was defined as that 
concentration which caused approximately a 50% change in cellular 
morphology of toxicity control cells. This toxicity determination, while 
subjective and approximate, was based on graded morphological changes 
observed at increasing levels of the test compounds, with 0% representing 
no morphological change and 100% representing total cell destruction. The 
therapeutic index (TI) is defined as the CDso/ED50. 
Inhibition of cytopathogenic effect and plaque reduction assays. 
Ribavirin was run in side by side assays in order to compare the sensitivity of 
the immunofluorescence antiviral assay to the more standard antiviral 
assays such as inhibition of viral CPE (15) and the PR (6) assays. In the CPE 
assay, the drug was added in triplicate to wells of a 96 well plate in one-half 
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log10 dilutions from 1000 ~J.g/ml to 1.0 ~J.g/ml. The plates were then scored 
when virus controls reached a maximum level of CPE. In these studies 
using PCV at an MOl of 0.001 this did not occur until approximately 12 days 
after virus infection and the maximum CPE was considered to be 1+. In the 
PR assay the test compound was incorporated into the overlay media and 
was then placed onto infected cell monolayers in 6-well plates . The 
monolayers in this assay were infected at an MOl of 0.0001. After 5 days of 
incubation, the plaques in the treated wells were counted and compared with 
those of the virus control wells. 
RESULTS 
Attempts to find a cell line in which PCV would produce consistent and 
quantifiable CPE. Several cell lines, noted in Materials and Methods, were 
used in an attempt to find a cell line that produced consistently quantifiable 
CPE when infected with PCV. This was done in order to use the inhibition 
of C:?E assay (15) that is used as a standard antiviral screening test in this 
laboratory. Only one cell line, Vero-76, showed slight viral CPE, in this case 
appearing 12 days p.i . PCV did not produce adequate CPE in any of the other 
cell lines that were tested. 
Antiviral activity of ribavirin, 3-deazauridine, (S)-DHPA, and ribavirin 
derivatives against PCV. An example of an antiviral test using the IFA 
procedure is seen in Table 1. Ribavirin was used as the test compound. 
Toxicity controls exhibited morphologic changes only at 1000 and 320 !!g/ml 
dose levels; the CDso was determined to be 1000 ~J.g/ml. Exposure of the 
infected cells to ribavirin resulted in total inhibition of fluorescent cells at 10 
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through 1000 !J.g/ml dosage levels; a 43% inhibition of infected cells was seen 
at 3.2 ~J.g/ml. The TI for ribavirin was calculated to be 217.4 in this test. 
Using the IFA procedure, the compounds described earlier were 
evaluated against PCV. The virus was found to be most sensitive to 
selenazofurin (Table 2). The data also indicate that selenazofurin had the 
greatest TI of the compounds tested . Ribavirin-5'-hemisuccinate and, as 
described above, ribavirin were very effective against PCV using this assay. 
In contrast, methyl groups incorporated at the 2- and 3- positions of the 
hemisuccinate side chain reduced the TI 21-fold . Ribavirin-5 '-
monophosphate and 3-deazaurid:Tle were also active against the virus. Very 
weak activity against PCV was seen with (5)-DHPA. 
The infected cells were easily distinguished from uninfected cells by the 
bright apple green fluorescence of the immunostain. There was virtually no 
background staining of the uninfected cells. The stain appeared to bind to 
the membrane and cytoplasmic components of the fixed, infected cells. The 
nuclei of the infected cells did not appear to bind any immunostain. This 
pattern would be consistent with ~he replication and maturation of PCV 
particles in the cytoplasm and their budding through of the cytoplasmic 
membrane of infected cells. 
Comparison of IFA with inhibition of viral CPE and PR antiviral assays. 
A comparison of the IFA to the inhibition of viral CPE and PR assays is 
shown in Table 3. The IFA sensitivity appeared comparable to that of the 
other two assays used although the PR assay appears to be slightly more 
sensitive than the IFA or the inhibition of viral CPE assay. This may be, in 
part, due to the relative MOl's used in the different assays, with the PR assay 
being infected with 10-20-fold less virus than the inhibition of viral CPE or 
IFA assays, respectively. Also, the PR assay required larger amounts of the 
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compound than either IFA or CPE procedure and the time to endpoint was 4 
days longer that that required in the IFA test. 
DISCUSSION 
The IFA procedure described here appears to be an acceptable tool for 
antiviral drug testing. By comparing the results obtained from evaluating 
the antiviral efficacy of ribavirin using several different antiviral assays, the 
IFA demonstrates several important advantages: 1) The IFA is essentially as 
sensitive as either of the other assays used in this stuc y, 2) it has the 
advantage of requiring much less compound than the PR assay, 3) the 
endpoint is much less ambiguous than that of the CPE assay in which 
reproducible, readily discernible PCV-induced CPE was difficult to achieve, 
and 4) the IFA assay can be performed in 24 h instead of the 5-12 days 
required for PR testing or CPE inhibition, respectively. The procedure 
worked well for evaluation of all nucleoside analogues used in this study. 
The relative costs of the three assays used in this study ar._ comparable, if 
the production costs of the monoclonal antibodies are not taken into 
consideration. This procedure can be adapted for use as an indirect method 
using virus-specific polyclonal sera and FITC-labeled secondary antibody. 
The monoclonal antibodies to PCV produced in our laboratories that were 
used for this study are not available commercially. 
The results reported here indicate that PCV is reasonably sensitive to 
selenazofurin, ribavirin, ribavirin-5 '-hemisuccinate, ribavirin-5'-
monophosphate, and 3-deazauridine. Selenazofurin and ribavirin have 
previously been reported active against PCV using PR tests (10), and 
ribavirin has also exhibited in vivo efficacy against this virus (7). 3-
~ 
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Deazauridine is known to inhibit a number of other RNA viruses, including 
rhino, influenza A and B, parainfluenza 1, and vesicular stomatitis viruses 
(9), as well as Gross and Rauscher murine leukemia viruses (14). Ribavirin-
5'-monophosphate exhibited both in vitro and in vivo efficacy against 
influenza A and B and murine hepatitis viruses (1). The aliphatic 
nucleoside (S)-DHPA has been reported to have a broad-spectrum antiviral 
activity (3) although prior to these experiments it had never been tested 
against PCV. The results of testing (S)-DHPA against PCV indicate that the 
compound was active only at the highest concentrations. This is the first 
report of antiviral testing with the other ribavirin derivatives described here. 
The loss of activity associated with the incorporation of methyl groups at the 
2- and 3- positions of the 5'-hemisuccinate of ribavirin indicates that steric 
hindrance may inhibit either the transport of the molecule into the infected 
cell or, more likely, the hydrolysis to free ribavirin. 
~ 
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TABLE III-1. Effect of ribavirin against Pichinde virus infection in Vero 
cells as determined by IFA procedure. 
Cone. 
(!lg/ml) 
1000 
320 
100 
32 
10 
3.2 
1.0 
0 
Cytotoxicitl 
(%) 
Fluorescent 
cells 
(No. of cells I well) 
50 0, 0, 0 
25 0, 0, 0 
0 0, 0, 0 
0 0,0,0 
0 0,0, 0 
0 133,89,57 
0 127, 146, 147 
0 171,235,178,114,173,102 
EDsob: 4.6!-lg/ml 
CDsoc: 1000 !lg/ml 
Tid: 217.4 
Mean Inhibition 
fluorescentof fluorescent 
cells/well cells (%) 
0 
0 
0 
0 
0 
93 
140 
162 
100 
100 
100 
100 
100 
43 
14 
0 
a As determined by microscopic examination of toxicity control wells, 
expressed as enlarged, flattened cells. The percent indicated is the 
approximate degree of enlargement and flattening that occurred. 
b EDso: 50% effective dose, determined by plotting concentration of drug 
versus percent inhibition on a semilogarithmic chart. 
c COso: 50% cytotoxic dose as determined by microscopic examination of 
toxicity control wells. 
d Therapeutic index= CDso/EDso. 
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TABLE III-2. Activity of nucleoside analogues against PCV as measured by 
IFA procedure. 
ED so a COso 
Drug ()lg/ml) ()lg/ml) Tic 
Selenazofurin <1.0 320 >320.0 
Ribavirin 6.0 1000 166.7 
Ribavirin-5'-hemisuccinate 14.7 >1470 >100.0 
Ribavirin-5' -monophosphate 15.8 >1000 >63.3 
3-Deazauridine 5.2 320 61.5 
Ribavirin-5'-(2,3-dimethyl) 
hemisuccinate 213.5 >1000 >4.7 
(S)-DHPA 471.0 >1000 >2.1 
• 
a EDso: 50% effective dose, determined by plotting concentration of drug 
versus percent inhibition on a semilogarithmic chart; each is an average 
of 1 to 4 experiments. 
b COso: 50% cytotoxic dose. 
c TI = CDso/ED50 
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TABLE III-3. Activity of ribavirin against PCV as measured by different 
antiviral assays in Vero cells. 
ED so Amt. required/ Time to 
Antiviral Assaya (J.!g/ml)b assay (mg)c endpoint (days)d 
CPE 3.2-10 5 12 
PR 1.0-3.2 50 5 
IFA 3.2-10 5 1 
a CPE =inhibition of cytopathogenic effect; PR =plaque reduction; IFA = 
immunofluorescence assay. 
b EDso's expressed as ranges, from multiple experiments. 
c Amount of compound required to make initial stock of 2000 J.!g/ml. 
d Time at which results could be determinec . 
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CHAPTER IV 
CHARACTERIZATION OF MONOCLONAL ANTIBODIES 
PRODUCED AGAINST PICHINDE VIRUS 
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Mouse monoclonal antibodies directed against Pichinde virus (PCV) 
were produced to evaluate their possible application as vehicles for the 
directed delivery of antiviral drugs or toxins to virus infected cells. 
Monoclonal antibodies PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were of the 
IgG2a subisotype and reacted with both acetone-fixed and live PCV-infected 
Vero-76 cells . Radioimmunoprecipitation of proteins from 35S-
me thionine-labeled PCV-infected cell lysates with PC4.9A6, PC4.9D3, 
PC4.7C2, PC4.8D2, and hyperimmune hamster serum showed that all the 
antibodies precipitated two different PCV proteins, one of 64,000 daltons, 
and another of 38,000 daltons. These proteins were, respectively, PCV 
nucleoprotein (NP) and a breakdown product of NP that was present in 
PCV-infected cells. Fluorescein-labeled PC4.9A6 (FITC-9A6) reacted 
optimally with PCV-infected acetone-fixed cells and did not stain 
noninfected cells. The staining of live PCV-infected cells with FITC-9A6 
revealed that >90% fewer infected cells were stained than were observed in 
similarly infected cells that were acetone-fixed prior to staining. Live PCV-
infected cells stained with FITC-9A6 appeared more rounded up and 
refractile than acetone-fixed PCV-infected cells. Both PCV-infected and 
noninfected live cells demonstrated some non-specific staining with FITC-
9A6, although this staining was readily discernible from the virus-specific 
staining. In vivo stained splenic macrophages derived from PCV-infected 
hamsters that had been injected with FITC-9A6 demonstrated a 400% 
increase in total fluorescence over similarly treated, non-infected cells when 
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analyzed by flow cytometry. This was an indication that FITC-9A6 does 
have some ability to specifically target PCV-infected cells in vivo and that it 
warrented further investigation into its use as a delivery vehicle for the 
directed delivery of either antiviral compounds or toxins. 
Arenaviruses are the etiological agents of several significant 
hemorrhagic diseases in humans, namely, Lassa fever, Argentine 
hemorrhagic fever, and Bolivian hemorrhagic fever. These diseases are 
spread by rodents that are asymptomatic carriers of the virus. These rodents 
shed large amount~ ot virus in their urine. Disease outbreaks most often 
occur in lesser developed areas of Africa and South America where it is 
often difficult to limit the contact between rural households and the rodents 
that harbor these pathogenic viruses. 
Although ribavirin (1-~-D-ribofuranosyl-1 ,2,4-triazole-3-carboxamide) 
has been shown to be effective in reducing the mortality of patients 
hospitalized with severe, acute Lassa fever there still exists a significant 
number of patients ·. :ho are not responsive to ribavirin therapy (10). 
Similar observations have been made using animal models of Argentine 
and Bolivian hemorrhagic fevers (7). Treatment of similarly infected 
individuals with immune plasma from patients with Lassa fever resulted 
in only slightly diminished mortality rates (7). Currently, more effective 
means of clinical intervention in arenaviral hemorrhagic diseases are 
needed in the areas of the world where these diseases are endemic. 
One method of enhancing the effectiveness of a drug or toxin is to target 
its delivery to the cell population of interest, whether in neoplastic or in 
virally induced diseases (2, 4, 12). Monoclonal antibodies were produced 
that were reactive with PCV-infected cells (1). This study reports on the 
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suitability of these monoclonal antibodies as possible vehicles for the in 
vivo delivery of antiviral compounds or toxins to PCV-infected cells in 
MHA hamsters. 
MATERIALS AND METHODS 
Cells. The Vero-76 cells used in this study were obtained from the 
American Type Culture Collection (Rockville, MD) . The cells were 
passaged in minimum essential media (MEM, GIBCO, Grand Island, NY) 
supplemented with 9% fetal bovine serum (FBS. Hyclone Labs, Logan, UT). 
For immunofluorescent assays in 96-well polystyrene plates (Corning, 
Corning, NY), 0.1 ml of cells diluted to a density of 4 x 105 cells/ml in MEM 
with 9% FBS was added to each well. Similar immunofluorescent assays 
were done using glass cover slips seeded with 0.3 ml of the same density of 
Vero-76 cells. 
Virus. PCV strain An 4763 was provided by Dr. Joseph D. Gangemi, 
University of South Carolina School of Medici:: ~, Columbia, SC. Virus 
stocks were prepared in Vero cells from twice plaque-purified PCV. The 
virus was grown at 37°C and was harvested 2-3 days after virus exposure, 
aliquoted into ampules, and stored at -90°C until used. The virus stock had 
a titer of 4 x 105 plaque-forming units (pfu)/ml and an immunofluorescent 
titer of 5 x 106 fluorescent foci-forming units/ml when stained with a 
PC4.9A6-fluorescein conjugate. 
Animals. The MHA hamsters used in this experiment were supplied by 
Charles River Laboratories, Inc. (Wilmington, MA). The hamsters were 
females of >10 weeks of age and weighed approximately 60-70 gat the onset 
of the experiment. The animals were quarantined for at least 24-48 h prior to 
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use. The hamsters were housed five per cage in polycarbonate cages with 
corn cob bedding and were provided with Wayne Lab Blox and tap water ad 
libitum. 
Monoclonal antibodies. Monoclonal antibodies PC4.9A6, PC4.9D3, 
PC4.7C2, and PC4.8D2 were produced against PCV as previously described 
(1) . Monoclonal antibody 33.6, reactive with an epitope on glycoprotein 2 
(GP2) that is conserved amongst all the arenaviruses, was provided by 
Micheal J. Buchmeier, Scripps Institute of Immunology, La Jolla, CA (18). 
Isotyping of monoclonal antibodies. The monoclonal antibodies 
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were isotyped and subisoty .•ea 
using a mouse antibody isotyping kit from Hyclone Laboratories (Logan, 
UT), as per manufacturer's instructions. Briefly, the kit was a sandwich 
ELISA done in a 96-well microtiter plate using a-phenylenediamine as the 
horseradish peroxidase (HRPO) enzyme substrate. The microtiter plates 
were read at 490 nm on a Bio-Tek (Winooski, VT) microplate reader. 
Normal mouse serum (NMS) was used as a positive control. 
Radioimmunoprecipitation of Pichinde virus antigens. Pichinde viru~ 
infected Vero-76 cells were labeled with 25-50 ~Ci/ml of Tran35S-label® 
(ICN Biomedicals, Inc., Irvine, California), a cellular hydrolysate of 
Escherichia coli grown in the presence of carrier-free 35S04=. This product 
contained 70 % L-methionine, 15% L-cysteine, and various non-labeled 
amino acids as described in the accompanying product literature. Infected 
and noninfected cells were methionine-starved with methionine-deficient 
media for 2 h prior to addition of the radiolabel. The cells were labeled at 
various times, typically at 36 h post-infection (p. i.), for 2-18 h, after which 
they were chased with media containing a 100-fold excess of cold 
methionine . 
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Infected and noninfected cells were harvested by scraping them from 
the flasks and pelleting them by centrifugation at 7500 x g. The cell pellets 
were resuspended in lysis buffer (0.1 M Tris, pH 8.0, 0.14 M NaCI, and 
0.025% sodium azide [TSA] with 1% Triton X-100, 1% bovine hemoglobin, 1 
mM iodoacetamide, 0.2 U aprotinin and 1 mM phenylmethylsulfonyl 
fluoride, [PMSF]) and were kept at 4°C for 1 h. After lysis of the cytoplasmic 
membranes the nuclei were pelleted by centrifugation and the supernatant 
containing solubilized membrane proteins and cytoplasmic components 
was collected and frozen in aliquots at -90°C. 
Prior to the immunoprecipitation of the radiolabeled antigens with the 
relevant monoclonal antibodies, the cell lysates were cleared with an 
irrelevant ascites fluid containing an IgG2a monoclonal antibody produced 
against an unrelated bacterial antigen. This reduced the nonspecific binding 
of the components of the cell lystate to the relevant monoclonal antibodies. 
The irrelevant ascites fluid was added to the cell lysates and incubated for 1 
hat 4°C. The nonspecific complexes were precipitated by addition of 50-100 
Jll of 10% suspension of Staphylococcus aureus Cowan strain II (Staph A) 
cells to the pretreated cell lysates. These cells express protein A on their 
surfaces. Protein A has a high affinity for the Fe portion of mouse IgG2a 
immunoglobulin molecules and can be used to precipitate antigen-antibody 
(Ag-Ab) complexes. The hybridoma cell culture fluids that contained the 
relevant monoclonal antibodies, PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 
were added to the precleared cell lysates, containing 106 counts per minute 
of radiolabel, and were incubated for 1-2 h at 4°C. The Ag-monoclonal 
antibody complexes were then precipitated by adding SO Jll of Staph A cells 
that had been washed twice with lysis buffer. The complexes were pelleted 
by centrifugation for 5 seconds in a microfuge (3000 x g, Hermie model 
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Z230A, National Labnet Co., Woodbridge, NJ). The Staph A-monoclonal 
antibody-antigen complexes were washed twice in cold dilution buffer (0.1% 
Triton X-100, and 0.1% bovine hemoglobin in TSA), once in cold TSA 
buffer, and once in cold 0.0625 M Tris-Cl, pH 6.8. The pelleted complexes 
were resuspended in 2x sample buffer (0.125 M Tris-Cl, pH 6.8, 4% SDS, 20% 
glycerol, 1 mM dithiothreotol [OTT), and 0.001% bromophenyl blue) and 
boiled for 3 min to dissociate the radiolabeled antigen from the complex. 
The Staph A cells were again pelleted by centrifugation and the supernatant, 
containing the now dissociated protein of interest, was immediately loaded 
onto a 10% polyacrylamide gel for electrophoresis (13). 
Polyacrylamide gel electrophoresis. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SD5-PAGE) was performed as described 
by Laemmli (8). Samples for electrophoresis were solublized by boiling 
them for 3 min in 2x sample buffer or in 2x nonreducing sample buffer that 
did not contain any reducing agent such as OTT or p-mercaptoethanol. 
Samples were loaded on to a discontinuous polyacrylamide gel consisting of 
a 4% stacking gel (final concentrations: 4% total [T] acrylamide 2.7% 
crosslinked [C] acrylamide, 0.1% SDS, and 0.125 M Tris-Cl, pH 6.8) poured 
over a 10% separating gel (final concentration: 10%T 2.7%C acrylamide, 
0.1% SDS, and 0.375 M Tris-Cl, pH 8.8). The gel apparatus was filled with 
tank buffer (0.025 M Tris-Cl, pH 8.3, 0.192 M glycine, and 0.1% SDS) and the 
solublized samples were loaded into the appropriate wells. A constant 
current of 20 rnA per gel was applied until the bromphenol blue tracking 
dye reached the bottom edge of the gel. Molecular mass markers 
(Diversified Biotech, Newton Centre, MA, molecular mass [m.m.] range 
12,700- 95,000 daltons) suitable for silver staining were included on the gels 
that were silver stained. 14C-Radiolabeled m.m. standards (Bethesda 
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Research Laboratories Life Technologies, Inc., Gaithersburg, MD, m.m. 
range 14,300- 200,000 daltons) were included in the gels that were used for 
fluorography. The gels were fixed in 10% (v /v) glacial acetic acid and 30% 
(v /v) methanol, treated with FluroHance (Research Products International 
Corp., Prospect, IL) according to manufacturer's instructions, dried and used 
to expose Kodak X-0-Mat X-Ray film, silver stained as described below, or 
used for electrophoretic transfer of the separated proteins to nitrocellulose 
for use in immunodetection. 
Silver staining of polyacrylamide gels. Polyacrylamide gels (0.75 mm 
thick) were fixed in 10'f. (v /v) glacial acetic acid and 30% (v /v) methanol 
overnight and washed (3 x 10 min) in 5% (v /v) glacial acetic acid and 10% 
(v /v) methanol to further remove any residual SDS. The gels were soaked 
in 0.3 mM potassium dichromate and 0.0032 N nitric acid for 5 min. The 
gels were washed (4 x 30 sec) in deionized water. The gels were placed in a 
solution of 0.12 M silver nitrate for 25 min under ambient light. The silver 
nitrate solution was decanted and the gels were washed quickly twice with 
0.28 M sodium carbona• 2 and 0.05% (v /v) formalin . The gels were 
developed in a third wash of this mixture until the bands reached the 
desired intensity. Development of the gels was stopped by immersing the 
gel in a solution of 1% acetic acid. The silver stained gels were dried onto 
paper backing. 
Immunodetection of proteins in cell extracts. Extracts of cells infected 
with PCV at an multiplicity of infection (MOl) of 0.1 and noninfected cells 
were prepared by the addition of lysis buffer containing 0.1 M Tris, pH 8.0, 
0.5% Triton X-100, 1 mM iodoacetamide, aprotinin (0.2 U/ml), and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis, MO) at 4°C for 1 
L 
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h. The nuclei were then pelleted by centrifugation and supernatants were 
aliquoted into vials and stored at -90°C until used. 
PCV-infected and noninfected cell lysates were subjected to SDS-PAGE 
prior to being transferred onto nitrocellulose employing the procedure of 
Towbin et a!. (14) . Proteins reactive to the monoclonal antibodies were 
detected using Auroprobe BLplus® (Janssen Biotech N . V., Piscataway, NJ) 
according to manufacturer's instructions. Total cell lysates were stained 
with AuroDye Forte® (Janssen Biotech) as per manufacturer's instructions. 
Detection of viral and cellular glycoproteins. Viral and cellular 
glycoproteins were detected on the electrophoretic nitrocellulose transfers of 
the PCV-infected and noninfected cell lysates using a method described by 
Clegg (3). Briefly, the blots were blocked with a solution of 2.5% bovine 
serum albumin (BSA) in PBS for 1 h at room temperature with agitation 
after which they were incubated in a solution of concanavalin A (Con A, 10 
J.tg/ml, Sigma, St. Louis, MO) in phosphate-buffered saline (PBS, Sigma, St. 
Louis, MO) with 0.5% Triton X-100 (Sigma, St. Louis, MO) for 1 h at room 
temperature with agitation. The transfers were w~Jhed (5 x 5 min) with 
washing buffer (PBS with 0.5% Triton X-100). The blots were incubated in a 
solution of HRPO (50 Jlg/ml, Sigma, St. Louis, MO) for 1 h at room 
temperature with agitation. The blots were again washed (5 x 5 min) with 
washing buffer. The viral and cellular glycoproteins were detected by 
incubating the transfers in a solution of 3,3'-diaminobenzidene (DAB, 0.5 
mg/ml, Sigma, St. Louis, MO) in Tris-Cl buffer, pH 7.6, with 0.04% NiCl2 
and 0.004% H202. Development was stopped by immersion of the blots in 
deionized water. 
Comparison of the binding of FITC-labeled PC4.9A6 monoclonal 
antibody to fixed and non-fixed PCV-infected cells. Vero-76 cells were 
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seeded onto glass cover slips in Petri dishes at a density of 1.2 x 105 
cells/ cover slip. At 24 h after the cover slips were seeded, the confluent 
cultures were infected with PCV diluted in maintenance medium (MEM 
with 2% FBS, 0.1% NaHC03, and 50 jlg gentamycin/ml). At 48 h p.i., the 
cells were either fixed with acetone for 5 min and stained with 6 jlg/ml of 
FITC-labeled PC4.9A6 conjugate or stained alive by diluting the PC4.9A6-
FITC conjugate directly into the maintenance medium at the same 
concentration. All cells, acetone-fixed or alive, were stained for 3 h with the 
conjugate after which they were rinsed with Evan's Blue stain in PBS and 
mounted onto a glass slide with a drop of elvanol mounting medium (6). 
The cells were then observed and photographed immediately under 400x 
magnification employing both Hoffman contrast and epifluorescent optics 
using a Nikon Diaphot microscope. 
In vitro targeting of PCV-infected spleen cells by FITC-labeled PC4.9A6 
monoclonal antibodies Two groups of MHA hamsters, PCV-infected (n=4) 
and noninfected (n=5), were used to investigate the in vitro targeting of the 
FITC-labeled PC4.9A6 conjugate to PCV-infected spleen cells. Infected 
hamsters used for in vitro targeting were infected subcutaneously (s.c.) with 
10 LDso units of PCV. Noninfected hamsters were included as controls. 
Both infected and noninfected hamsters in the in vitro targeting study 
were sacrificed on day 9 p.i. by cervical dislocation and their spleens were 
removed. The spleens were placed into 10 ml of Puck's balanced salts 
solution and a spleen cell suspension was made using a Stomacher 
laboratory apparatus (Tekmar Co., Cincinnati, OH). The cell suspension was 
pelleted by gentle centrifugation and the contaminating red blood cells were 
lysed by hypotonic shock by suspending the pellet in 9 ml of water for 10 
seconds after which 1 ml of lOx PBS was added to the suspension. The 
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remaining cells were pelleted and washed twice in RPMI 1640 with 15% 
FBS. Prio~ to staining, 106 cells were aliquoted into a test tube and the 
samples were pelleted by centrifugation and resuspended in 1 ml of RPMI 
1640. Cells were stained for 1 h at room temperature with 60 J.lg/ml of FITC-
labeled PC4.9A6 after which the macrophage population of the spleen cell 
suspension was subjected to flow cytometry analysis using a Coulter 
Electronics (Hialeah, FL) EPICS flow cytometer. 
In vivo targeting of PCV-infected spleen cells by FITC-labeled PC4.9A6 
monoclonal antibodies in MHA hamsters. PCV-infected (n=4) and 
noninfected (n=S) hamsters from the in vivo targeting groups were injected 
i.p . with 0.5 ml of 60 J.lg/ml FITC-PC4.9A6 conjugate on day 9 p.i., 8 h prior 
to being sacrificed. Hamsters in both groups were sacrificed by cervical 
dislocation, the spleens were removed, and spleen cell suspensions were 
prepared for flow cytometry as described above except that the suspensions 
were not subjected to any further staining at anytime during the 
experiment. Spleen cell suspensions were then subjected to flow cytometry 
analysis as described below. 
Flow cytometry analysis of in vivo and in vitro stained hamster spleen 
cell suspensions. Flow cytometry was performed with an EPICS-C flow 
cytometer (Coulter Electronics Inc., Hialeah, FL), equipped with an argon 
laser tuned to 400 mW at the 488 nm line. Cells were carried in Isoflow 
sheath fluid (Coulter) through a 76 micron tip. Fluorescence data for FITC 
were obtained using a bit-map format, gated on the forward light scatter 
versus right-angle light scatter histogram. The bit map was used to isolate 
cells of interest, splenic macrophages, and to exclude debris and doublets. 
Fluorescent signals were processed through a three-decade log amplifier and 
displayed on a 256-channel scale. Fluorescence intensity was standardized 
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using 10 Jlm latex beads (Immunocheck, Coulter) and adjusting the laser 
power to place the log-green histogram in channel 119. Other settings 
remained constant for all samples. Data were stored and later analyzed 
using the Cytologic® software package (Coulter). 
RESULTS 
Subisotype of anti-PCV monoclonal antibodies. Monoclonal antibodies 
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were found to be of the IgG2a 
subisotype (Table 1). 
Staining of acetone-fixed and live PCV-infected and noninfected Vero-
76 cells using FITC-labeled PC4.9A6 monoclonal antibody. When acetone 
fixed PCV-infected Vero-76 cells were stained with FITC-conjugated 
PC4.9A6 and viewed under epifluorescence optics there was intense, apple-
green virus-specific fluorescent staining observed. Usually 30-50 infected 
cells were present in areas of fluorescence which appeared to overlap in 
many of the regions of the coverslips (Fig. 1A). The acetone-fixed 
noninfected cell controls showed no virus specific staining and very little 
background staining (Fig. 1 B) . Using Hoffman contrast optics, no 
morphological or pathological distinctions were observed between the 
acetone-fixed PCV-infected cells and the noninfected cells (Figs. 1C and 10, 
respectively). 
When live, unfixed, PCV-infected cells that had been stained with FITC-
labeled PC4.9A6 were observed using epifluorescence optics virus-specific as 
well as some nonspecific staining was observed. The virus-specific staining 
observed was similar to that seen with the acetone-fixed cells, except that 
the specifically stained areas contained only a few (1-5) fluorescent cells (Fig. 
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2A). When the same field was viewed using Hoffman optics, the cells that 
were fluorescing appeared much more rounded-up and more refractile (Fig. 
2C) than the cells that had been acetone-fixed prior to staining (Fig. lC). 
Nonspecific staining occurred in both the infected and noninfected cells 
and was characterized by an even, diffuse, light green fluorescence of entire 
individual cells. There was only one cell per foci that took up the stain in a 
nonspecific manner (Fig. 2B) . This staining faded rapidly under the UV 
light, and no longer fluoresced within 30 to 90 seconds of being placed in the 
UV beam of the microscope. There were no morphological differences 
observed in the cells tha : demonstrated nonspecific staining in either the 
infected or noninfected groups when observed under Hoffman optics 
(Figures 2C and 2D, respectively). 
Characterization of the PCV peptide binding specificity of the anti-PCV 
monoclonal antibodies. The monoclonal antibodies PC4.9A6, PC4.9D3, 
PC4.7C2, and PC4.8D2 were used to immunoprecipitate 355-methionine-
labeled peptides from PCV-infected cell lysates. Monoclonal antibody 33.6, 
hyperimmune hamster sen: .:l (HHS), and an unrelated hybridoma ascites 
fluid (FOX-NY) were included as positive (33.6 and HHS) and negative 
(FOX-NY) controls, respectively. Monoclonal antibodies PC4.9A6, PC4.9D3, 
PC4.7C2, and PC4.8D2 all immunoprecipitated the same viral peptides, a 
64,000 dalton protein, and a 38,000 dalton protein (Fig. 3). HHS reacted with 
the same two viral peptides. Monoclonal antibody 33.6, specific for an 
epitope on GP2 that is conserved amongst all arenaviruses (17), did not 
precipitate any virus proteins in this assay. The negative control FOX-NY 
also did not precipitate any arenavirus proteins. None of the antibody 
preparations precipitated proteins from noninfected Vero-76 celllysates. 
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Detection and localization of PCV glycoproteins on nitrocellulose from 
electrophoretic transfers of PCV-infected and noninfected cell lysates. 
Glycoproteins present in both PCV-infected cells and noninfected cells were 
detected using a Con A-HRPO detection system (3). This system is based on 
the ability of the divalent lectin Con-A to bind to the glycoproteins 
immobilized on the nitrocellulose membrane and also to the HRPO 
detection enzyme that is also a glycoprotein. Using this system, only the 
glycoproteins present in the lysates were detected and localized on the 
nitrocellulose membrane. In the lane containing the PCV-infected cell 
lysate (lane 3 of Fig. 4) there were two bands that d0 not appear in the lane 
containing the noninfected cell lysate (lane 4 of Fig. 4) . These two bands 
that were unique to the PCV-infected cell lysate are glycoproteins (GPl and 
GP2) of 57,000 daltons and 33,000 daltons in size. Monoclonal antibody 33.6 
reacted with the 33,000 dalton glycoprotein (GP2) in the PCV-infected cells 
lysate (lane 2 of Fig. 4) and did not react with any proteins found in the 
noninfected cell lysate lane (lane 1 of Fig. 4). Monoclonal antibodies 
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 did not re~ :t consistently in this 
assay giving spurious results that included high background in both the 
infected and uninfected celllysates or not reacting at all. 
In vitro and in vivo targeting of PCV-infected MHA hamster spleen 
cells by FITC-labeled PC4.9A6 monoclonal antibody. When FITC-labeled 
PC4.9A6 was used to stain both PCV-infected and noninfected spleen cells in 
vitro, there was only very weak reactivity with the cells as evidenced by 
very low fluorescent intensity and cell numbers when the stained spleen 
cells were analyzed by flow cytometry (data not shown). When the same 
antibody was used to target the infected cells in vivo the FITC-labeled 
PC4.9A6 reacted with the infected splenic macrophages. This is evidenced 
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by a 400% increase in the overall fluorescent intensity and total fluorescent 
cell numbers of in vivo stained splenic macrophages as opposed to the same 
population of cells taken from in vivo stained, noninfected animals (Table 
2, Figs. SA and SB, Figs. 6B, and 6C). Background fluorescence of 
nonstained, normal spleen macrophages is shown in Figure 6A. 
DISCUSSION 
The anti-PCV monoclonal antibodies PC4.9A6, PC4.9D3, PC4.8D2, and 
PC4.7C2 were evaluated with regard to their isotype and subisotype, 
reactivity with PCV-infected and noninfected acetone-fixed and living cells, 
PCV peptide binding specificity, and their ability to target infected splenic 
macrophages in the MHA hamster model of PCV-induced hemorrhagic 
fever. This study was undertaken to investigate the suitability of these 
monoclonal antibodies as delivery vehicles for the targeted delivery of 
antiviral compounds. These monoclonal antibody-drug conjugates could 
possibly be used as therapeutic regimens for the treatment of human 
arenaviral hemorrhagic fevers such as Lassa fever, Argentine hemorrhagic 
fever, and Bolivian hemorrhagic fever for which there is still a substantial 
mortality rate in regions where the viruses that cause these diseases are 
endemic. 
All four of the monoclonal antibodies were initially screened using 
epifluorescence microscopy first against infected, acetone-fixed cells and 
secondly, against living PCV-infected cells. All four demonstrated at least 
some ability to bind to nonfixed, infected cells. Monoclonal antibody 
PC4.9A6 was selected as the candidate for further, more extensive, 
evaluation on the basis of its ability to bind to nonfixed, living infected cells. 
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Hoffman contrast microscopy, used in conjunction with epifluorescence 
microscopy, revealed that PC4.9A6 was reacting with living PCV-infected 
cells that appeared to be more rounded and refractile than similar cells that 
had been fixed with acetone and then stained. It also showed that the 
PC4.9A6 was reacting with a much smaller population of cells under 
nonfixed conditions. Apparently, the intact, live, unfixed infected cells 
were more resistant to staining with PC4.9A6. The cells that were 
specifically stained with PC4.9A6 may have had membranes that were more 
porous or less resistant to penetration by the FITC-labeled conjugate. 
Another explanation for this occurrence was that the infected cells, at some 
point during the infection, had the PCV nucleoprotein on their surface as 
shown by Zeller eta!. (19). Alternative routes of antigen presentation, such 
as the exocytosis of protease degradation products from previously 
endocytosed virus particles, may account for these observations (11) . 
The monoclonal antibodies that were produced in our laboratories 
immunoprecipitate two proteins from infected cell lysates, one of 64 
kiloDaltons (kDa) and another of 38 kDa. Harnish et a!. (5) have reported 
that proteins of these sizes correspond to PCV nucleoprotein (NP) and a 
breakdown product of NP, respectively. It must be noted that Vezza eta!. 
(15) have reported molecular masses of 66 kDa for NP, 64 kDa for GP1, and 
38 kDa for GP2. The molecular masses of the proteins isolated with our 
monoclonal antibodies tend to confirm the observations of Harnish et a!. (5) 
with regard to molecular masses of the PCV proteins species . The 
monoclonal antibody 33.6 did not demonstrate any ability to bind GP2 using 
the radioimmunoprecipitation technique. The failure of the HHS and 
monoclonal antibody 33.6 to precipitate any of the viral glycoproteins in this 
assay may be due to the 12 h chase period used to radiolabel the infected 
58 
cells. Because the glycoprotein precursor protein (GPC) is readily cleaved 
into GPl and GP2, a lengthy chase period (>9 h) could result in the cleavage 
and secretion into the medium of all radiolabeled viral glycoproteins. This 
would result in the disappearance of the radiolabeled glycoproteins from 
the infected cells lysates (5). 
Immunodetection of viral and cellular proteins transferred to 
nitrocellulose (Western blotting), using PC4.9A6, PC4.9D3, PC4.7C2, and 
PC4.8D2 as the primary antibodies, did not yield satisfactory results due to 
high background when these antibodies were used (data not shown). This 
was in part due to the autonucleation of the silver intensifier used to 
enhance the signal of the gold-conjugated secondary antibody used in the 
immunodetection system. Another explanation for this lack of reactivity in 
the Western blotting system was that the antibodies were reactive with a 
conformational-dependent epitope that was destroyed or denatured during 
the processing of the gels and the blots, although measures were taken to 
minimize this problem. Antibody 33.6 did react with a single 33 kDa 
.;lycoprotein when it was used as the primary antibody for Western blotting. 
Glycoprotein detection using concanavalin A and HRPO to localize cellular 
and viral glycoproteins confirms that there is a major PCV glycoprotein 
band at 33 kDa that most likely corresponds to GP2. The other viral 
glycoprotein, GPl, migrated at 57 kDa. The PCV glycoprotein precursor 
protein (GPC, -80 kDa) was not detected using this assay. Further, 
glycoprotein detection did not reveal a viral glycoprotein band at 64 kDa or 
at 38 kDa. The presence of viral glycoproteins in these positions would 
have been a strong indication that PC4.9A6, PC4.903, PC4.8D2, and PC4.7C2 
did indeed react with viral glycoprotein antigens that may be more readily 
accessible to antibodies on the surface of PCV-infected cells. 
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Although PC4.9A6 apparently is not maximally bound to all live, 
virally infected cells, the antibody does have some ability to target splenic 
macrophages from PCV-infected hamsters when it was administered in 
vivo. Splenic macrophages from PCV-infected hamsters that were 
inoculated with FITC-labeled PC4.9A6 on day 9 p.i . 8h prior to being 
sacrificed demonstrated an average 400% increase in total fluorescence and 
fluorescent intensity over similar uninfected animals when the samples 
were analyzed using flow cytometry. Similar splenic macrophages, stained 
in vitro and run in parellel, did not demonstrate this same targeting effect. 
This suggests that the av;: ;Jability of free antigen may influence the uptake 
of the FITC-conjugate. It is possible that PCV may produce an over-
abundance of NP and that this may be accessible to the immune system. 
Thus, the FITC-conjugate may be able to bind this free antigen and be 
carried into the macrophages. Another possibility is that the infected 
macrophage may express portions of NP on its surface, perhaps in the 
context of a class II histocompatability antigen, in its role as the antigen-
presenting cell (APC) to thf immune system. Recent advances in the study 
of antigen presentation by macrophages indicate that both antigens found 
on the surface of virus particles as well as proteins from the interior of the 
virion can be expressed on the surface of the APCs (9, 11, 16, 19). This may 
allow for the conjugate to bind and be taken up into the cell even though 
the conjugate is directed toward an internal viral protein. Lafon and Lafage 
have demonstrated the antiviral activity of monoclonal antibodies directed 
toward the internal proteins of rabies virus (9). Also, Mills et a!. have 
demonstrated that cytotoxic T cells were induced to proliferate when 
exposed to APCs that expressed the internal matrix protein of influenza 
virus (11). Thus, the monoclonal antibodies tested here may target infected 
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cells although they are directed toward an internal PCV protein. At least a 
portion of the binding may be attributable to the presence of Fe receptors on 
the surface of the macrophage. This appears the most likely explanation for 
the binding of the FITC-labeled 9A6 to macrophages in noninfected 
animals. The levels seen in this case more closely parallel the levels from 
the in vitro targeting data. These lower levels may be attributable to low or 
nonexistent levels of free antigen in the animals or in the cell culture 
medium in which the in vitro targeting cells were stained. 
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B 
D 
FIG. IV-1. Comparison of acetone-fixed PCV-infected and noninfected 
Vero-76 cells stained with FITC-labeled PC4.9A6 using epifluorescence and 
Hoffman contrast optics. A: Infected cells viewed with epifluorescence; B: 
Noninfected cells viewed with epifluorescence; C: Same microscopic field 
as A viewed with Hoffman optics; D: Same microscopic field as B viewed 
with Hoffman optics (1200 x magnification). 
62 
A 
c D 
FIG. IV-2. Comparison of live, unfixed PCV-infected and noninfected 
Vero-76 cells stained with FITC-labeled PC4.9A6 using epifluorescence and 
Hoffman contrast optics . A: Infected cells viewed with epifluorescence 
(note stippled staining of infected cells); B: Noninfected cells viewed with 
epifluorescence; C: Same microscopic field as A viewed with Hoffman 
optics; D: Same microscopic field as B viewed with Hoffman optics. (1200 x 
magnification). 
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FIG. IV-3. lmmunoprecipitation of proteins from PCV-infected Vero-
76 cells radiolabeled with 35S-methionine by monoclonal antibodies 
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2. Lanes are labeled, n = noninfected 
cell lysate; i = PCV-infected cell lysate. 
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FIG. IV-4. Western blot of PCV-infected and noninfected Vero-76 cells. 
Lane 1: noninfected Vero-76 cells probed with 33.6 as primary antibody. 
Lane 2: PCV-infected Vero-76 cells probed with 33.6 as primary antibody. 
Lane 3: Glycoprotein detection of PCV-infected Vero-76 cells. Lane 4: 
Glycoprotein detection of noninfected Vero-76 cells. 
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FIG. IV-5. Flow cytometry histograms of MHA hamster splenic 
macrophages stained in vivo with FITC-labeled PC4.9A6. A: Noninfected 
hamster spleen macrophages (n=5); B: PCV-infected hamster spleen 
macrophages (n=4). 
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FIG. IV-6. Comparison of flow cytometry histograms of splenic 
macrophages from MHA hamsters. A: Unstained, normal hamster spleen 
macrophages; B: Noninfected hamster spleen macrophages stained with 
FITC-labeled PC4.9A6; C: PCV-infected hamster spleen macrophages 
stained with FITC-labeled PC4.9A6. 
66 
67 
Table IV-1. Reactivity of anti-PCV monoclonal antibodies in mouse 
subisotype immunoassays. 
Antibody IgM IgGl IgG2a IgG2b IgG3 IgA 
PC4.9A6 + 
PC4.9D3 + 
PC4.7C2 + 
PC4.8D2 + 
NMsa + + + 
a NMS = normal mouse serum. 
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Table IV-2. Comparison of areas and mean channels from histograms A 
and B of Figure 5. 
Histogram 
Percent of histogram to 
the right of cursora 
A (Noninfected hamster) 
B (PCV infected hamster) 
8.33 
41.81 
Mean 
Channelb 
36.3 
41 .2 
a Percentage of total area of the histogram found to the right of the cursor. 
The cursor was set to exclude background fluorescence as determined by 
the autofluorescence of nonstained MHA hamster splenic macrophages 
as seen in Figure 6A. 
b The mean channel of the FITC-9A6 fluorescence of the PCV-infected 
hamsters is shifted 5.1 units to the right of the mean channel for the 
normal control hamsters. 
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CHAPTER V 
CHARACTERIZATION OF THE RESPONSE OF MHA HAMSTERS TO 
TREATMENT WITH ANTI-PICHINDE VIRUS MONOCLONAL 
ANTIBODY-GELONIN IMMUNOCONJUGATE 
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An immunotoxin (IT) was produced by the conjugation of a phytotoxin, 
gelonin, to a Pichinde virus (PCV) reactive monoclonal antibody, PC4.9A6. 
This immunotoxin was tested in vivo in PCV-infected MHA hamsters, a 
model for arenaviral hemorrhagic disease. The IT was not active against the 
disease at the dosage tested and by the treatment route employed in this 
study. The positive control, ribavirin, demonstrated a highly significant 
(P<O.OOS) increase in survivors. Serum titrations indicated that 3 of the 5 IT 
toxicity control animals had developed some humoral response that 
inhibited the binding of PC4.9A6 to infected target cells. The hamsters did 
not show any response to the gelonin moiety of the IT. 
The targeting of anti-tumor drugs and phytotoxins to neoplastic and 
virally-infected cells using immunologically reactive macromolecules is a 
relatively new field of endeavor that has introduced a new degree of 
specificity to the pharmacological action of these compounds. By chemically 
linking the drugs or toxins to large protein molecules such as monoclonal 
antibodies (1, 9, 11) or cellular virus receptors {5), a new dimension has been 
added to the delivery of these compounds to specifically selected and targeted 
cell populations. Fifty percent inhibitory dosages (IDsos) in the range of 10-11 
M are not uncommon in determinations made using monoclonal antibody-
toxin conjugates against cancer cells (8) whereas the 50% cytotoxic dosage 
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(COso) in antigen-negative cells is on the order of 10-7 M resulting in a 
therapeutic index (T. I. = COso/IDso) of 10,000. 
In·a recent :Study, Ch:audhary·era.t.-(5) used the C04 antigen as a means of 
targeting Pseudomonas exotoxin A to cells infected with the human 
immunodeficiency virus (HIV), this resulted in specific killing of HIV-
infected cells. Human phase I trials using a mouse anti-human-COS 
monoclonal antibody conjugated with ricin A chain have been undertaken 
in patients with refractory chronic lymphocytic leukemia (9). This study 
demonstrated that the treatment was well tolerated, although no beneficial 
effect was observed in the patients. 
In vitro and in vivo studies in other than human subjects cannot be 
extrapolated directly to the human patient. In vitro and in vivo therapeutic 
efficacy is not a guarantee that the therapy will work in humans as is 
demonstrated in the human phase I leukemia study by Hertler et a!. (9) 
referred to above. Even though the IT was binding to and saturating all of 
the available binding sites on the lymphocytes of the patients, there was still 
no therapeutic efficacy in preventing the recurrence of the leukemia. Thus, 
surface binding is not the only criteria to be addressed in the development of 
monoclonal antibody-directed delivery systems. The IT must also be readily 
endocytosed, eventually releasing the toxin or drug into the cell (4). Antigen 
density is another criteria that must be considered in the development of 
vehicles for targeted delivery. Sufficient antigen must be readily accessible to 
the IT. Low antigen density will prevent the uptake and subsequent release 
of the toxin into the target cell. The simple fact that a molecule binds to the 
surface of a cell does not ensure that this molecule is well suited as a targeted 
delivery vehicle (8) . 
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Prior studies indicated that FITC-labeled PC4.9A6 did target PCV-infected 
cells in vivo. This is significant because it indicated that an immunoconju-
gate did reach the target population of cells. Thus, the in vivo efficacy of a 
novel IT, PC4.9A6 conjugated with the ribosomal-inactivating protein 
gelonin, against PCV-induced arenaviral hemorrhagic fever in MHA ham-
sters was evaluated in this study. Currently available therapeutic treatments 
still have room for improvement in combating arenaviral hemorrhagic dis-
eases in humans. By targeting the gelonin to PCV-infected cells, it was 
hoped that a therapeutic effect could be observed due to the selective elimi-
nation of PCV-infected cell~ irom the still healthy cell population and the 
concurrent reduction in the systemic toxicity of the toxin. Although this 
therapeutic effect did not occur the experiment has helped to elucidate some 
of the problems to be considered in using IT for antiviral therapy. 
MATERIALS AND METHODS 
Cells. The Vero-76 eel' - used in this study were obtained from the 
American Type Culture Collection (Rockville, MD) . The cells were passaged 
in minimum essential media (MEM, GIBCO, Grand Island, NY) 
supplemented with 9% fetal bovine serum (FBS, Hyclone Labs, Logan, UT) . 
For immunofluorescent assays in 96-well polystyrene plates (Corning, 
Corning, NY), 0.1 ml of cells diluted to 4 x ros cells/ml in MEM with 9% FBS 
was added to each well. 
Animals. The MHA hamsters used in this experiment were supplied by 
Charles River Laboritories, Inc. (Wilmington, MA) . The hamsters were 
females that weighed approximately 40-50 g at the onset of the experiment. 
The animals were quarantined for 24-48 h prior to use. The hamsters were 
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housed five per cage in polycarbonate cages with corn cob bedding and were 
provided with Wayne Lab Blox and tap water ad libitum. 
Titration of PCV An4763 6-3-86 (B) virus pool in MHA hamsters. 
Hamsters were infected subcutaneously (s.c.) with 0.2 ml of one-half logw 
dilutions (l0-1.5 to 10·6) of PCV pool, PCV strain An 4763 of 6-3-86 (B) . 
Animals were observed and counted on a daily basis. All days of death were 
recorded. LDso and LD9o determinations were made using the method of 
Reed and Muench (15). 
Ribavirin and PC4.9A6-gelonin irnmunotoxin. 1-p-D-ribofuranosyl-1,2,4-
triazole-3-carboxamide (ribavirin) was provided by f ,e U. S. Army Medical 
Research Institute for Infectious Diseases via Technassociates, Inc. 
(Rockville, MD). The IT, PC4.9A6 conjugated with the A chain phytotoxin 
gelonin (Sigma, St. Louis, MO), was prepared by Dr. Bill B. Barnett (Utah 
State University, Logan, UT). The IT was shown to inhibit in vitro protein 
synthesis when the disulfide bridge connecting the gelonin to the 
monoclonal antibody was chemically reduced. The immunotoxin was 16% 
gelonin by weight (personal communication, B. B. Barn ·.:t) . 
In vivo determination of antiviral efficacy of the PC4.9A6-gelonin irn-
munotoxin. Hamsters used for the determination of antiviral effectiveness 
of the PC4.9A6-gelonin irnmunotoxin (IT) were all infected s.c. with 0.2 ml of 
a PCV suspension containing one LD9o (80 immunofluorescent cell forming 
units) of PCV strain An 4763. The infected hamsters were randomly divided 
into six treatment groups of ten animals each. The treatment groups were as 
follows : i) PC4.9A6 treated (0.56 mg/kg / day); ii) Gelonin treated (0.1 
mg/ kg/ day); iii) PC4.9A6/ gelonin mixture (0.56 mg/kg/ day of PC4.9A6 + 0.1 
mg/kg/ day of gelonin); iv) PC4.9A6-gelonin IT (0.66 mg/kg/ day); v) 
Ribavirin (40 mg/kg/day); and vi) Saline. All treatments were performed 
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once a day intraperitoneally (i.p.) on days 3-5 post-infection (p.i.) except for 
the ribavirin-treated group that was treated twice a day on days 1-14 p.i. The 
uninfected animals were housed completely separate from the infected 
animals. The toxicity control group consisted of five uninfected, PC4.9A6-
gelonin IT-treated hamsters. The normal controls were five uninfected, 
untreated hamsters. Toxicity and normal controls were weighed 
individually immediately prior to the first treatment and then again prior to 
all subsequent IT treatments. After day 7 p.i., they were weighed on a weekly 
basis. Toxicity controls were bled via the orbital sinus on days 3, 10, 17, 24, 
and 31 p.i. 
Production of hamster anti-gelonin serum. Four PCV-infected hamsters 
that had been treated with gelonin and had survived the course of the 
experiment were boosted with 0.1 ml i.p. of a 1 mg/ml dilution of gelonin in 
sterile phosphate buffered saline (PBS), 8 weeks after the initial injections of 
gelonin. Serum was collected from these animals and pooled 4 days after the 
second injection of gelonin. Anti-gelonin activity of the hamster serum was 
determined using an indirect enzyme-linked immunosorbent assay (ELISA) 
as described below. 
ELISA for the detection of the inhibitory effects of toxicity control 
hamster sera on the binding of PC4.9A6 to PCV-infected Vero-76 cells. 
Twenty-four hour confluent monolayers of Vero-76 cells in microtiter plates 
were infected with PCV were fixed as previously described (3), and stored at 
-20°C until used. The cells were infected with a dilution of PCV that 
maximized the observable fluorescence of the acetone-fixed infected 
monolayers when stained with a PC4.9A6-FITC conjugate . Ten-fold 
dilutions (10-1 to 10-4) of serum collected from the IT toxicity control animals 
were made in dilution buffer (PBS with 0.1% BSA (Jannsen, Piscataway, NJ] 
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and 0.1% sodium azide [Kodak, Rochester, NY]). To each dilution of hamster 
serum (0.9 ml) was added 0.1 ml of a 60 ~g/ml dilution of purified PC4.9A6 
antibody (final concentration ·6 ~g/ml) ; The dilution tubes were incubated in 
a waterbath at 37°C for 1 h. Triplicates of the dilutions were plated (25 
~!/well) on the fixed, infected microtiter plates. Normal hamster serum, 
PC4.9A6 alone (6 ~g/ml), rabbit anti-PC4.9A6 serum (1 :100 dilution) with 6 
~g/ml PC4.9A6, pooled IT toxicity serum without PC4.9A6, and nontreated 
blanks were included as controls. The plates were wrapped in Saran Wrap® 
and incubated for 1 h at 37°C. After incubation, the plates were washed three 
times with dilution buffer and 50 ~I of a 1:1000 dilution of goat anti-mouse 
IgG-urease conjugate (Sigma, St. Louis, MO) was added to each well. Urease 
is an enzyme isolated from Canavalia ensiformis (Jack bean) that is not 
found in mammalian cells. Urease catalyzes the cleavage of ammonia from 
urea causing an increase in the pH of weakly buffered solutions. This 
increase in pH is detected, either visually or spectrophotometrically, as a 
change in the color from yellow to purple of the pH indicator bromcresol 
purple in the urease chromogen (13) . The plates were incubated for 2 h at 
37°C, after which the urease conjugate was decanted from the plates and the 
plates were washed three times with water. Urease chromogen (80 mg/1 
bromcresol purple, 0.15 mM NaOH, 0.1% urea, and 0.2 mM EDTA, pH 4.6, 
100 ~!/well) was added to the plates, and the plates were incubated until the 
positive controls reached an endpoint. Absorbance at 590 nm was read on a 
BioTek microplate reader. 
ELISA for the detection of anti-gelonin antibodies in hamster sera. 
Round bottom ELISA plates (Immulon 2, Dynatech Labs, Inc., Chantilly, VA) 
were coated with gelonin (10 ~g/ml) by adding 0.1 ml/well of gelonin 
diluted in coating buffer (0.1 M carbonate, ph 9.6). The plates were incubated 
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for 24 h at 4°C, after which they were washed four times with water and 
allowed to dry. Coated plates were stored at -20°C until used. 
Remaining protein binding sites on the gelonin-coated plates were 
blocked prior to use by adding 100 Ill of blocking buffer (5% BSA in PBS) to 
each well and incubating at 4°C overnight. Dilutions (l0-1 to 10-4) of hamster 
sera in dilution buffer were made. To each well of the microtiter plate was 
added 25 Ill of the appropriate dilution of hamster sera and the plates were 
allowed to incubate for 1 hat 37°C. The plates were washed three times with 
dilution buffer. Fifty Ill/well of the urease conjugate (Sigma) diluted 1:1000 
in '.1.ilution buffer was added to the plates and they were further incubated at 
37°C for 2 h. The plates were then washed three times with water and 100 
Ill/well of urease chromogen was added. Wells treated with normal 
hamster serum and hamster anti-gelonin serum, as well as nontreated wells, 
were included as controls. Plates were incubated until positive control wells 
reached an endpoint. Absorbance at 590 nm was then read on a BioTek 
microplate reader. 
r ~atistical evaluation. Increases in survivors were evaluated using Chi-
square analysis with Yates' correction. Mean survival time of the treated 
hamsters was evaluated using Student's t-test. Data from the mouse anti-
PC4.9A6 assays and from the mouse anti-gelonin assays were analyzed by 
analysis of variance using a randomized block design. 
RESULTS 
Titration of PCV in MHA hamsters. Hamsters infected with PCV had an 
average day of death of 10.7 ± 2.1 days (Fig. 1). The LDso titer of this virus 
pool was 1.6 x 106 LDso/ml. 
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Effects of i.p. treatment with PC4.9A6-gelonin IT. The data from the 
experiment performed to investigate the antiviral efficacy of the IT is 
summarized in Table 1. There was no significant increase in survivors or in 
mean survival time in any of the treatment groups, except for the ribavirin 
group (10) that showed a highly significant (P<0.005) increase in survivors. 
Increase in mean survival time for the ribavirin-treated group would have 
been statistically significant except for one death that occurred on day 20 p.i. 
(Fig. 2). Days of death data are shown in Figure 3. 
Toxicity of PC4.9A6-gelonin IT. Data from the toxicity controls collected 
during the first week of treatrne ·"lt suggests that there may have been some 
host toxicity associated with the administration of the IT, as indicated by the 
decrease in the average weights of the IT-treated animals after day 3 p.i (Fig. 
4). The toxicity controls were able to overcome this initial toxicity and went 
on to gain normal or above amounts of weight after day 4 p.i . (Fig. 5). 
Normal controls did not manifest any loss of weight throughout the course 
of this experiment. 
Humoral response of MHA h: msters to IT treatment. Analysis of the 
data collected from ELISA for the inhibition of PC4.9A6 binding to PCV-
infected Vero-76 cell by dilutions of serum collected weekly from the IT 
toxicity control animals revealed that there was a highly significant (P<O.OOl) 
inhibition (Table 2, Figs. 6 and 7). At the 10-1 dilution of hamster serum 
taken at week 1 (Fig. 6), there is a significant decrease in absorption, 
indicating that there is a component in this dilution of serum that prevents 
the binding of PC4.9A6 to infected cells. When the same data was plotted 
with respect to the time of sample collection and holding the dilution 
constant (l0-1 dilution, Fig. 7), the data indicate that there were 3 of the 5 
animals whose serum appeared to at least partially block PC4.9A6 binding. 
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The data from the 10-2 dilution of hamster serum, plotted in the same 
fashion, demonstrated that this effect was no longer present at this dilution 
(Fig. 8). The same was true for the lQ-3 and J0-4 dilutions in this assay (data 
not shown). Positive control serum, rabbit anti-PC4.9A6, was able to 
completely inhibit antibody binding in this assay (Fig. 6). 
The same dilutions (l0-1 to J0-4) of hamster serum were tested for their 
gelonin binding activity employing an indirect ELISA. There was no 
significant reaction of the toxicity control hamsters to the gelonin moiety of 
the IT as evidenced by the lack of reactivity in these assays (Table 2). Positive 
control serum (hamster anti-gelonin) did react in this assay rF1g. 9) . Normal 
hamster serum used as a negative control in this assay demonstrated more 
reactivity with gelonin than the IT toxicity control animals serum at a 10-1 
dilution, although it did not surpass the positive control serum in its 
reactivity with gelonin (Figs. 9 and 10). The apparent reactivity of the 
normal hamster serum was abolished at the 10-2 dilution (Fig. 11). It should 
also be noted that pre-treatment serums, collected from the IT toxicity 
control animals prior to IT treatment, did not demonstrate inc-eased gelonin 
reactivity at the 10-1 dilution (Figs. 9 and 10). 
80 
DISCUSSION 
Several recent studies using monoclonal antibodies conjugated to A 
chain toxins, including gelonin, have suggested that these immunotoxins 
are able to specifically kill either lymphoid or tumor cells in vitro and in 
vivo (12, 14). A similar approach using Pseudomonas exotoxin A conjugated 
to recombinant human CD4 has been shown to selectively kill HIV-infected 
cells in vitro (5). 
Because of the success in using these immunotoxins against cancer and 
HIV infection, an application of this approach was sought for the inhibition 
of PCV-infected cells. Gelonin appears to be particularly attractive for this 
application because it is not toxic to intact cells and must be transported into 
the cell in order for it to inhibit protein synthesis via the enzymatic 
inactivation of ribosomes (6, 16). The IT used in this s tudy is approximately 
16% gelonin by weight and has been shown to inhibit in vitro protein 
synthesis when the disulfide bonds linking the gelonin to the antibody are 
chemically reduced (B. B. Barnett, Utah State University, Logan, UT, 
personal communication) . 
The data from this experiment indicate that the IT is not having the 
desired effect in preventing hemorrhagic disease in this model (Table 1). 
The positive control, ribavirin (10), confirmed that the hemorrhagic disease 
model could be successfully treated by conventional antiviral chemotherapy. 
The PC4.9A6 only, gelonin only, PC4.9A6 + gelonin, and saline treated 
controls also did not have a significant effect on extending the survival time 
or number of survivors in the infected hamsters. The lack of IT activity in 
this model could be due to a number of factors such as insufficient dosage of 
IT, the blocking of the antigen binding site of the antibody by free viral 
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antigen in the blood and serum, the timing of the adminstration of the IT, 
or that the IT is not taken up by the infected cells. The dosage of IT used in 
this experiment is similar to the dosages that have shown tumor and HIV-
infected cell killing activity in other systems (5, 7) . In addition, the host 
weight loss occurring in the toxicity control animals treated with IT suggests 
the maximum tolerated dose was approached in this experiment. 
Serum from 3 of the 5 IT toxicity control hamsters demonstrated 
significant ability to inhibit the binding of PC4.9A6 during the first week after 
the animals were treated with IT. The apparent reaction of these hamsters to 
the antigen-binding portion of PC4.9A6 of the IT was indicative th? ~ there 
may have been an antiidiotypic response induced due to treatment with the 
IT. The humoral response of these hamsters was weaker than the anti-
PC4.9A6 serum that was used as a positive control, although still highly 
significant, but these animals were treated with what would be considered a 
very poor immunization schedule, if induction of anti-PC4.9A6 antibody 
was to be the end of the experiment. Because the hamster and the mouse 
appear to be genetically closely related, an antiidiotypic response by a hai .• ster 
to the immunoglobulin is an interesting effect. It should be noted that the 
appearance of the PC4.9A6-inhibitory substance in the serum of the toxicity 
control hamsters does not appear to develop as a classical immune response 
to a foreign antigen, that is with a well defined lag period that gradually 
increased over time to a maximum titer. The inhibition was noted 
immediately after treatment with the IT and dropped off within a week of 
the cessation of treatment. The total anti-PC4.9A6 response of the IT toxicity 
control hamsters was not done because of the innate cross reactivity of anti-
mouse reagents with hamster antibodies. This genetic relatedness of the 
mouse and the hamster may be what was responsible for the development of 
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the "antiidiotypic" response of the hamster to the mouse immunoglobulin. 
It is conceivable that the only region of the immunoglobulin to which the 
hamster could react was the hypervariable region of the mouse 
immunoglobulin and that this response was what blocked that binding of 
PC4.9A6 to PCV-infected cells in the ELISA. 
In general, the phytotoxins such as ricin, abrin, and gelonin are 
considered to be immunogenic in animals (1) . The lack of a humoral 
immune response by the hamsters to the gelonin indicates that there must 
have been only very low amounts of gelonin on the antibody molecule. 
Since the IT was 16% gek'lin by weight, this indicates that there was 
probably only one or two molecules of the toxin on the antibody molecule. 
This may not have been enough to induce an adequate immune response to 
the phytotoxin, though it would have been sufficient to induce the catalytic 
inactivation of the 28 S ribosomal subunits of the cells if the toxin had 
penetrated to the interior of the infected cells. 
In conclusion, there are several possible explanations for the lack of 
reactivity of the monoclonal ar.:ibody toxin conjugate that was tested in this 
PCV-MHA hamster model of arenavirus-induced hemorrhagic disease. The 
immunotoxin was probably reaching at least some of the infected target cells 
in the animals. This was demonstrated in an earlier report (Chapter 4). The 
lack of reactivity in this system could be due to lack of expression of PCV 
nucleoprotein (NP) on the surface of the infected cells to which this antibody 
could bind to early in the infection process. It is possible that low levels of 
this antigen in the serum or other serum components such as antiidiotypic 
antibody directed against the paratope of PC4.9A6, would not allow this 
antibody to bind readily to the infected cells. There may not have been 
enough virus replication and infection of the target cells by days 3, 4, and 5 
83 
p .i. for IT to be targeted. If this is the case, another antibody, directed against 
an antigen expressed earlier on the surface of infected cells, should be 
selected as the target antigen. 
Another possibility is that killing the infected cells is not sufficient to 
stop the virus infection or that virus replication in some other way eclipses 
the activity .of the IT. If antigen availability is required prior to the targeting 
of the IT to infected cells, then there may already be enough virus assembled 
in the infected cells to go on and infect another round of cells after the cell is 
inactivated by the IT. This condition may be further aggravated if the 
immunotoxin was taken up into the cell and the toxin p0rtion was 
hydrolyzed from the IT, even though this was a desirable occurrence in order 
for the inactivation of ribosomes to occur. The hydrolyzed toxin would 
then have lost its ability to penetrate any more infected cells, due to the 
nature of the A chain toxin, and would be subjected to immediate clearance 
from the animal (2). 
This experiment pointed out the large number of variables that require 
consideration in attempting to target toxins using monoclonal a- tibodies. 
Surface reactivity or reactivity with live cells should not be the only 
considerations given to screening antibodies for their potential as toxin 
delivery vehicles. By incoporating a step in the initial monoclonal antibody 
screening procedures that allows for the evaluation of many candidate 
monoclonals, perhaps a more critical evaluation of the specific monoclonals 
can be made. This step could take the form of an indirect assay using goat 
anti-mouse, or another such antibody, conjugated with the toxin of interest 
to evaluate the targeting potential of all candidate monoclonal antibodies. 
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Figure V-1. Day of death histogram for the titration of PCV 
in MHA hamsters. Titration of PCV pool 6-3-86 (B) in 
6 week old female MHA hamsters. Mean day of death 
was 10.7 ± 2.1 days. 
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Figure v-2. Mean day of death of PCV-infected MHA hamsters 
by experimental treatment groups. There were no significant 
differences in the day of death of any of the treatment groups. 
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Figure V-3. Day of death histogram of PCV-infected MHA hamsters 
by experimental treatment groups. The positive control ribavirin 
demonstrated a significant increase in survivors. 
No other treatment demonstrated a significant effect. 
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Figure V-4. Average weights of MHA hamsters from experiment 
days 3 to 6. IT-treated hamsters demonstrated a decrease 
in weight following the first day of treatment. 
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Figure V-5. Weekly average weights of IT toxicity and normal MHA 
hamster controls. Toxicity controls did not demonstrate any cumulative 
toxic effects over the course of the experiment. 
88 
t 
0 
-d 
iii 
+I ] 
0 
"' !!:
.. 
u ; 
-e 
0 
<ll 
..c 
< -1+-~~~~~~~~~~~~~~ 10 100 1000 10000 100000 
1/Dilution 
Figure V-6. ELISA of the inhibitory effects of IT toxicity control hamster 
sera on PC4.9A6. Sera from 3 of 5 hamsters demonstrated significant inhibitory 
effects on PC4.9A6 binding to PCV-infected cells at week 1 at a 1:10 dilution. 
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Figure V-7. ELISA of the effects of IT t0xicity control hamster 
sera on PC4.9A6 (1:10 dilution). Effect of IT toxicity control hamster 
sera on the inhibition of PC4.9A6 binding to PCV-infected cells, absorbance 
plotted with respect to time. 
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Figure V-8. ELISA of the effects of IT toxicity control hamster sera 
on PC4.9A6 (1 :100 dilution) . Effect of IT control hamster sera on the 
inhibition of PC4.9A6 binding to PCV-infected cells, absorbance 
plotted with respect to time. 
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Figure V-9. ELISA of the gelonin binding activity of IT toxicity 
control hamster sera. Hamster anti-gelonin serum was the 
positive control. Normal hamster serum showed slightly 
increased anti-gelonin activity. 
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Figure V-10. ELISA of the gelonin binding activity of IT toxicity 
control hamster sera (1 :10 dilution). Normal hamster serum 
demonstrated slightly elevated gelonin binding activity, 
absorbance plotted with respect to time of sample. 
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Figure V-11. ELISA of the gelonin binding activity of IT toxicity 
control hamster sera (1:100 dilution). Normal hamster serum 
no longer demonstrated increased gelonin binding activity, 
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94 
95 
Table V-1. Effect of i.p. administrationa of PC4.9A6-gelonin IT on PCV-
infection in 3-4 week old MHA hamsters. 
Start of Dose No. Survivors/ Mean survival 
Treatmenta Treatmentb (mg/kg/day) Total timec (days) 
PC4.9A6 only 72 h post 0.56 0/10 10.5 
Gelonin 72 h post 0.10 4/10 13.0 
PC4.9A6/Gelonind 72 h post 0.56/0.10 1/10 13.8 
PC4.9A6-Gelonin JTe 72 h post 0.66 0/10 10.7 
Ribavirinf 24 h post 40.0 9/10g 20.0 
Saline 72 h post 0 4/20 12.3 
Toxicity controls: The IT toxicity controls all survived at a similar dose level 
and all lost weight after the first day of treatment, although they did begin to 
gain weight after the third day of treatment. Normal controls did not exhibit 
this loss of weight (Fig. 2). 
a Treatment once daily on days 3, 4, and 5 p .i. unless otherwise noted. 
b Relative to virus inoculation. 
c Animals dying on or before day 21. 
d A noncovalently linked mixture of the antibody PC4.9A6 and gelonin. 
e A covalently linked conjugate of PC4.9A6 and gelonin. 
f Treatment twice daily beginning 24 h p.i. on day 1 to day 14. 
g P<0.005. 
Table V-2. Analysis of variance of the anti-PC4.9A6 and the anti-gelonin 
activity of serum collected from toxicity control MHA hamsters for 
experimental weeks 0, 1, and 2. 
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Source of 
variance 
Anti-PC4.9A6 activity Anti-gelonin activity 
Main Effects 
Hamster (H) 
Dilution (D) 
Error (Hx D) 
Time (T) 
Error (H x T) 
Interactions 
Dilution x 
Dpa 
4 
3 
12 
2 
8 
Time 6 
Error (H x [D x T]) 24 
Total 59 
a Degrees of freedom. 
b Not significant. 
F value P value F value P value 
112.3 <0.001 30.35 <0.001 
9.624 <0.01 5.435 <0.05 
8.702 <0.001 <1 N . S.b 
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CHAPTER VI 
SUMMARY AND FUTURE DIRECTIONS 
Although treatment of Pichinde virus (PCV)-infected hamsters with 
immunotoxin (IT) did not prevent the development of disease, this model 
of directed delivery does demonstrate the potential for the in vivo targeting 
of PCV-infected cells. As is shown in chapter IV, the flourescein-PC4.9A6 
conjugate (FITC-9A6) demonstrated the ability to specifically bind to PCV-
infected cells. This is an indication that the system was effective in targeting 
immunoconjugates and that the process of conjugation did not destroy the 
ability of the monoclonal antibody to bind to infected cells. The lack of 
antiviral activity of the IT treatment used in this study could be due to a 
number of different reasons such as insufficient toxin on the conjugate to 
effectively kill the cell, though one molecule of toxin should have been 
adequate if it was taken into the cell. Another possibility is that the toxin 
was cleaved from the monoclonal antibody and eliminated from the animal 
prior to the antibody reaching the target cell. Also, the surface binding of 
monoclonal antibodies to infected cells may not be sufficient to ensure 
delivery of the toxin to the interior of the cell. It should be noted that viral 
antigen on the surface of a cell is considered to be on its way out of the cell as 
it is incorporated into a viral particle and not returning to the interior of the 
cell. Thus, there are a number of possible reasons that this particular IT 
treatment regimen was not effective. The optimization of several 
parameters, such as the viral target antigen, the appropriate toxin, the most 
efficient means of covalently linking the toxin to the antibody, as well as the 
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trreatment route and schedule, needs to be undertaken before this approach 
to the antiviral immunoconjugate therapy can be utilized successfully. 
Initially, there is a need to demonstrate, in vitro, if possible, that virus 
replication and spread to other noninfected cells can be prevented by using a 
targeted toxin delivery system based on either polyclonal or monoclonal 
amtibodies. This could take the form of an indirect screening procedure in 
wrhich polyclonal sera or an extensive panel of monoclonal antibodies, 
dcirected against a number of viral antigens and immunologically distinct 
ejpitopes, are used as the primary antibody. This could also include the 
testing of several different isotypes and subisotypes of antibodies, perhaps 
th1at are directed against the same epitope, in order to determine the effect of 
is•otype and subisotype on antibody uptake into infected cells. The secondary 
amtibody should be directed against the immunoglobulin from the species 
fnom which the polyclonal sera or monoclonal antibodies were derived. The 
secondary antibody could then be conjugated with any of a number of 
plhytotoxins or bacterial toxins such as gelonin, ricin A chain, abrin, 
d iiphtheria toxin, or Pseudomonas exotoxin A to name a few. Inhibition of 
either viral CPE or fluorescence due to viral antigen would be indicative of a 
successful combination of primary and secondary antibodies. An in vitro 
screening system for antiviral activity appears to be the only practical and 
ce>st effective alternative for screening the large numbers of potential 
primary and secondary antibody combinations, although it may not be as 
ef-fective in ensuring the delivery of the biologically active macromolecules 
to the target cells. 
In vitro targeting could also be investigated as a possible screening 
method using fluorescent microscopy. By employing secondary antibodies 
fluorescently tagged with a green molecule, the surface binding of the 
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primary antibody could be investigated in live cells. The Fe binding of the 
live cells could be blocked by using an unlabeled, irrelevant antibody derived 
from a species other than that from which the primary antibody was 
prepared. This would allow for the detection of virus-specific reactivity of 
the primary antibody on the surface of infected cells. In a parallel 
experiment, the secondary antibody that has been conjugated with the toxin 
molecule could be added to the cells. Following this step, a third or tertiary 
antibody, directed against the toxin moiety of the IT, bearing a red fluorescent 
label could be added . This would allow for the detection of toxin on the 
surface of infected cells when probed with the secondary antibody. This 
could be performed on cells that had been fixed or on live cells in order to 
demonstrated binding and uptake. Similar experiment could be performed 
using radiolabeled primary, secondary, and tertiary antibody preparations. 
Also, in vivo experiments could be done similar to those performed in 
chapter V, once the basic parameters had been optimized in vitro. 
Once this system has been optimized, it would be an excellent system for 
the screening of antiviral drug-monoclonal antibody conjugates in order to 
evaluate the efficacy of these compounds in combating viral disease. An 
approach similar to that described for immunotoxin evaluation could be 
taken in developing indirect screening procedures for the evaluation of 
antiviral drug-monoclonal antibody conjugate therapy. 
In conclusion, the development of monoclonal antibody-directed drug 
or toxin delivery systems is not simply a ~atter of producing antibodies and 
then using them for targeting infected cells. Surface binding of monoclonal 
antibodies to infected cells, though it is an important criterion, does not 
appear to be the sole criterion for the selection of an antibody for use in this 
targeted delivery system. The selection of antibodies that target and deliver 
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toxins or drugs to infected cells does appear to be an extremely complex 
process that requires the optimization of many parameters before optimal 
results can be observed. The questions with regard to which antibodies are 
best suited for use in this system may best be answered by developing an 
indirect procedure for the screening of large numbers of potential antibodies. 
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